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Q fever is an ubiquitous zoonosis caused by an resistant intracellular bacterium, Coxiella burnetii. In certain areas, Q fever can be
a severe public health problem, and awareness of the disease must be promoted worldwide. Nevertheless, knowledge of Coxiella
burnetii remains limited to this day. Its resistant (intracellular and environmental) and infectious properties have been poorly
investigated.Furtherunderstandingoftheinteractionsbetweentheinfectedhostandthebacteriaisnecessary.Domesticruminants
are considered as the main reservoir of bacteria. Infected animals shed highly infectious organisms in milk, feces, urine, vaginal
mucus, and, very importantly, birth products. Inhalation is the main route of infection. Frequently asymptomatic in humans
and animals, Q fever can cause acute or chronic infections. Financial consequences of infection can be dramatic at herd level.
Vaccination with inactive whole-cell bacteria has been performed and proved eﬀective in humans and animals. However, inactive
whole-cell vaccines present several defects. Recombinant vaccines have been developed in experimental conditions and have great
potential for the future. Q fever is a challenging disease for scientists as signiﬁcant further investigations are necessary. Great
research opportunities are available to reach a better understanding and thus a better prevention and control of the infection.
1.Introduction
Q fever was ﬁrst described in 1935 in Queensland, Australia,
during an outbreak of a febrile illness of unknown origin
(Query fever) among abattoir workers [1]. It was subse-
quentlyclassiﬁedas a “Category “B” critical biological agent”
by the Centre for Diseases Control and Prevention and is
considered a potential weapon for bioterrorism [2]. Q fever
is a public health concern throughout the world [3]. While Q
fever is an OIE notiﬁable disease, it remains poorly reported
and its surveillance is frequently severely neglected.
Q fever is a zoonotic bacterial disease. Domestic rumi-
nants (cattle, sheep, and goats) are considered as the main
reservoir for the pathogen which can infect a large variety of
hosts, mammals (humans, ruminants, small rodents, dogs,
andcats)andalsobirds,ﬁsh,reptiles,andarthropods[4–14].
Itwasreportedtobeahighlyinfectiousdiseaseinguineapigs
duringexperimentalintraperitonealinfections[15,16].Both
in animals and humans, however, Q fever infections remain
poorly understood [17, 18] and their prevalence have been
underestimated for many years [17].
2. CausalAgent
The causal agent of Q fever is Coxiella burnetii,a no b l i g a t e
intracellular Gram-negative bacterium of the Legionellales
order, which was ﬁrst observed as a rickettsia-like organism
in the spleen and liver of mice inoculated with the urine of2 International Journal of Microbiology
the abattoir workers [19–22]. Its predilected target cells are
the macrophages located in body tissues (e.g., lymph nodes,
spleen, lungs, and liver) and the monocytes circulating in the
blood stream [23].
Two diﬀerent antigenic forms of Coxiella burnetii can
be distinguished [24]. The diﬀerence between phase I and
phase II bacterial forms resides in the variation of the
surface lipopolysaccharide (LPS) as classically described for
enterobacteria [25]. Only phase I bacteria have a complete
LPS on their surface and are virulent bacteria [26]. Phase I
bacteria can be isolated from a naturally infected individual
or from animals infected in a laboratory [27, 28]. On the
other hand, phase II bacteria have an incomplete LPS due
to a spontaneous genetic deletion of 25,992bp [29]a n da r e
nonvirulent [28]. Phase II bacteria occur during serial
passageinanimmunologicallyincompetenthost,suchascell
cultures or fertilized eggs [27–29]. The deleted chromosomal
region comprises a high number of genes that are predicted
to function in LPS or lipooligosaccharide biosynthesis, as
well as in general carbohydrate and sulfur metabolism [30].
However, in Australia, the study by Thompson et al. [29]a n d
a later study by Denison et al. [31] on the genome of phase II
human strains by polymerase chain reaction (PCR) reported
the absence of truncated genes or of deletions. The Institute
for Genomic Research has suggested that at least two other
chromosomalregionsareimplicatedinphasetransition[29].
Antigenic variation of Coxiella burnetii is important for
serological diagnosis and elaboration of vaccines. Indeed,
serologically, anti-phase II antibodies (IgG and IgM) are
found at high levels in acute Q fever, whereas anti-phase I
antibodies (IgGandIgA)arefoundathighlevelsonlyduring
chronic infection [28].
Several genetic studies have been performed on Coxiella
burnetii. The genome of the American Nine Mile strain was
sequenced completely in 2003 [32]. The chromosome varies
i ns i z ef r o m1 . 5t o2 . 4 ·106 base pairs and was highly var-
iable among diﬀerent C. burnetii strains. Occasionally, a 33
to 42kb plasmid (depending on the plasmid considered)
can be observed but its function remains to be determined
[33]. Bacterial isolates can be identiﬁed by a probe to
16S ribosomal RNA (rRNA), which is highly conserved
[34]. Genetic heterogeneity of Coxiella burnetii is limited
with approximately 30 distinct variants [35]. According
to experimental studies, bacterial strains vary in their
pathogenic eﬀect [36–39]. Masuzawa et al. [40] studied
the macrophage infectivity potentiator gene (Cbmip of
654-base DNA) and the sensor-like protein gene (qrsA of
1227-base DNA) sequences between eleven strains. Their
results demonstrated that Cbmip and qrsA sequences were
highly conserved (>99%) and did not explain diﬀerences
in pathogenicity [40]. Furthermore, three diﬀerent plasmids
have been identiﬁed in Coxiella variants [41]: QpH1, QpRS,
and QpDG [42, 43]. Another plasmid (QpDV) has been
isolated in a strain from a human case of endocarditis
[44]. Plasmids diﬀer by size and genomic sequence. How-
ever, several identical genomic sequences are present in
all plasmids. In bacteria without plasmids, these sequences
are found on the chromosome [41]. Generally, plasmids
are of little interest for identiﬁcation of microorganisms
because they are not critical for survival and can infect a
large variety of organisms [41]. However, Coxiella burnetii
plasmids have proven to be useful because diﬀerent strains
contain diﬀerent plasmids. In fact, QpH1, QpRS, and QpDV
were present in diﬀerent genotypes and were associated
with diﬀerence in pathogenicity in the study by Frazier
et al. [41]. Moreover, Savinelli and Mallavia [45]r e p o r t e d
that, in human patients, the QpH1 and the QpRS plasmids
(or plasmidless strains containing QpRS-related plasmid
sequences) were associated with acute and chronic infection,
respectively. However, later studies by genomic restriction
fragment length polymorphism analysis, plasmid typing, or
lipopolysaccharide analysis, on a larger number of strains
did not conﬁrm their results. Indeed, recent data shows
that genetic variation has an apparent closer connection
with the geographical source of the isolate than with clinical
presentation[33,46].Moreover,hostfactorsseemtobemore
important than genomic variation for development of acute
or chronic infection [47, 48]. According to the recent report
by the OIE [49], no speciﬁc genotype is associated with acute
or chronic infection, with a particular clinical outcome, or
with a speciﬁc host.
3. Pathogenesis
The most important route of infection is inhalation of
bacteria-contaminated dust, while the oral route is consid-
ered of secondary importance. Once inhaled or ingested,
the extracellular form of Coxiella burnetii (or SCV after
small-cell variant) attaches itself to a cell membrane and is
internalized into the host cells. Phagolysosomes are formed
afterthefusionofphagosomeswithcellularacidiclysosomes.
The multiple intracellular phagolysosomes eventually fuse
together leading to the formation of a large unique vacuole.
Coxiella burnetii has adapted to the phagolysosomes of
eukaryotic cells and is capable of multiplying in the acidic
vacuoles [50]. In fact, acidity is necessary for its metabolism,
including nutrients assimilation and synthesis of nucleic
acids and amino acids [51]. Multiplication of Coxiella bur-
netii can be stopped by raising the phagolysosomal pH using
lysosomotropic agents such as chloroquine [52, 53]. The
mechanisms of Coxiella burnetii survival in phagolysosomes
a r es t i l lu n d e rs t u d y .M oe ta l .[ 54] and Akporiaye and Baca
[55] identiﬁed three proteins involved in intracellular sur-
vival: a superoxide dismutase, a catalase, and a macrophage
infectivity potentiator (Cbmip). Redd and Thompson [56]
foundthatsecretionandexportofCbmipwastriggeredbyan
acid pH in vitro. Later, studies by Zamboni and Rabonovitch
[57] and by Brennan et al. [58] demonstrated that growth
of Coxiella burnetii was reduced by reactive oxygen inter-
mediates (ROI) and reactive nitrogen intermediates. Hill
and Samuel [59]a n a l y z e dCoxiella burnetii’s genome and
identiﬁed 2 acid phosphatase enzymes. They demonstrated
experimentally that both a recombinant acid phosphatase
(rACP) enzyme and Coxiella burnetii extracts had a pH-
dependent acid phosphatase activity. Moreover, rACP and
bacterial extracts were capable of inhibiting ROI response by
PMN despite their exogenous stimulation by a strong PMNInternational Journal of Microbiology 3
stimulant. Inhibition of the assembly of the NADPH oxidase
complex was found to be the mechanism involved [59]. In
vitro studies on persistently infected cells with phase I and
phase II bacteria reported a similar mitotic rate in infected
and noninfected cells [23]. Moreover, the authors frequently
observed asymmetric cellular divisions in infected cells and
suggested that this phenomenon could allow maintenance of
persistent infection [60].
The intracellular cycle of Coxiella burnetii leads to the
formation of two development stages of the bacterium
known as “small-cell variant” (SCV) and “large-cell vari-
ant” (LCV) [61–64]. SCV is the extracellular form of the
bacterium. Typically rodshaped, SCVs are compact mea-
s u r i n gf r o m0 . 2t o0 . 5 μm with an electron-dense core
[61]. According to previous studies, SCVs are considered to
be metabolically inactive and capable of resisting extreme
conditions such as heat, desiccation, high or low pH,
disinfectants, chemical products, osmotic pressure, and UV
rays [19, 22, 62, 64, 65]. Their resistance in the environment
(pseudospores) would enable the bacteria to survive for long
periods of time in the absence of a suitable host. SCVs of
Coxiella burnetii a r er e v e r s i b l e[ 17]. Indeed, once inhaled
or ingested, the SCV attaches itself to a cell membrane
and is internalized. After phagolysosomal fusion, the acidity
of the newly formed vacuole induces activation of SCV
metabolism and its development into LCV. During the
morphogenesis from SCV to LCV, no increase in bacterial
number is reported [66]. LCV is considered to be the
metabolically active intracellular form of Coxiella burnetii.
They are more pleomorphic than SCVs. Their cell wall is
thinnerandtheyhaveamoredispersedﬁlamentousnucleoid
region. They can exceed 1μmi nl e n g t h[ 61]. Intracellular
growth is relatively slow with a doubling time of ap-
proximately 8 to 12 hours [24]. LCVs can diﬀerentiate into
spore-like bacteria by binary asymmetrical division. The
endogenous spore-like forms can undergo further devel-
opment and metabolic changes until ﬁnally reaching the
SCV form. Finally, cell lysis, or possibly exocytosis, releases
the resistant bacteria into the extracellular media [67]. The
physical and biological factors responsible for the spor-
ulation-like process remain unknown. According to Rousset
et al. [17], most natural infections by Coxiella burnetii
are probably due to SCV or pseudospores present in the
environment. Thus, decreasing the prevalence of Q fever
infections requires a strict limitation of the environmental
population of Coxiella pseudospores by using hygienic
preventive measures [17]. Studies on the immune reaction
in naturally or experimentally infected individuals have
suggested that cellular immunity and the synthesis of IFNγ
are essential for control of Coxiella burnetii infection [68–
70]. Helbig et al. [69] demonstrated the predominant role
of IFNγ, its level of production determining the outcome of
infection. Indeed, IFNγ has been successfully tested to treat
Q fever in patients not responding to antibiotic treatment
[71, 72]. A study by Shannon et al. [70] reported that the
development of protective antibody-mediated immunity in
vivo was found to be independent of the cellular Fc receptors
and of the complement [70]. The major part of vaccine-
derivedhumoralresponseconsistsofIgGantibodiesdirected
against proteins [73, 74]. Several studies report that natural
humoral response to Coxiella burnetii is directed against
both protein and glycolipid fractions [75–78]. Chen et al.
[79] identiﬁed 8 new CD4+ T-cell epitopes. However, all the
CD4+ T cell epitopes did not lead to B-cell stimulation and
speciﬁc antibody production. Koster et al. [80] reported that,
in chronic infections, peripheral blood lymphocytes do not
proliferatewhenexposedtoCoxiella burnetiiantigensdespite
proliferating when exposed to other antigens or mitogens.
This was not observed in acute infection [81]. In addition,
Shannon et al. [82] observed that Coxiella burnetii phase I
cells appeared almost invisible to dendritic cells.
Hormonalchangesduring pregnancycauseimmunomo-
dulation in the female body causing reactivation of the
organism.Thisimmunomodulationhasbeenadvancedasan
explanation for the increased multiplication of the organism
in the placenta [83].
Further research is more than necessary to fully under-
stand the complex processes developed by Coxiella burnetii
to enter and infect a speciﬁc host cell, to resist in the intracel-
lular and extracellular environment, and its ability to cause
illness. Moreover, a better understanding of the immune
system reaction to infection would give an insight into the
processes developed by the bacterium and by the host that
determinetheﬁnaloutcomeofdisease(asymptomatic,acute,
or chronic).
4. Epidemiological andClinicalAspects
4.1.RoutesofInfection. Inhalationisthemostcommonroute
of infection in both animals and human [84–86]. Under
experimental conditions, inhalation of a single C. burnetii
can produce infection and clinical disease in humans [87].
However, similar studies have not been done in animals [88].
As mentioned above, domestic animals are considered the
main reservoir for the pathogen [89–91]. Infected animals
contaminate the environment by shedding Coxiella burnetii
in milk, feces, urine, saliva [13, 92], and very importantly
in vaginal secretions, placenta, amniotic ﬂuids, and other
products of conception [13, 92–99]. Coxiella burnetii also
spreads by wind causing infections at a distance from the
initial source of bacteria [93, 96, 100, 101].
In domestic ruminants, milk is the most frequent route
of pathogen shedding [97]. Currently, controversy remains
concerning the possibility of infection by oral route [102].
Results of previous studies on the subject are considered
inconclusive [7, 103–106]. OIE advises not to drink raw
milkoriginatingfrominfectedfarms[49].Furtherresearchis
requiredtoclarifytheprobabilityofinfectionbyoralroute.If
infection by oral route is proven to be eﬃcient, the suﬃcient
number of pathogens capable of causing Q fever should be
determined [17].
Human-to-human transmission does not usually occur
[49, 107] although it has been described following contact
with parturient women [108, 109]. In addition, cases of
sexual transmission of Q fever have been reported [110–
112]. Currently, risk of transmission through blood trans-
fusion is considered negligible [113, 114]. Transplacental4 International Journal of Microbiology
transmission, intradermal inoculation, and postmortem
examinations have been associated with sporadic cases of Q
fever [115–118].
4.2. Q Fever in Domestic Animals and Wildlife
4.2.1. Cattle. Q fever is widespread in livestock, and its sero-
prevalence is thought to have increased in recent years [33].
Often neglected in the diﬀerential diagnosis, Q fever can
persist in a herd causing great ﬁnancial losses on the long
term [94].
In ruminants, well-known manifestations of Q fever are
abortion, stillbirth, premature delivery, and delivery of weak
oﬀspring [3]. However, these dramatic clinical manifesta-
tions are generally only expressed in sheep and goats. In
cattle, Q fever is frequently asymptomatic. Clinically infected
cows develop infertility, metritis, and mastitis [94]. In
addition, C. burnetii was found to be signiﬁcantly associated
with placentitis [119, 120]. Placental necrosis and fetal
bronchopneumonia were also signiﬁcantly associated with
the presence of Coxiella burnetii in the trophoblasts [119].
Unlike humans and experimentally infected cows [121],
naturally infected ruminants rarely present respiratory or
cardiac signs. Beaudeau et al. [122] and Guatteo et al. [92]
performedrespectivestudiesonsheddingofCoxiella burnetii
by infected cows. In the study by Guatteo et al. [92], the
apparent proportion of shedders in clinically infected dairy
herds among the cows sampled was 45.5%. Milk was the
mostfrequentpositivesampleforthebacteriumcomparedto
feces and vaginal mucus samples. The percentage of positive
samples of each type was 24.4, 20.7, and 19%, respectively.
65.4% of sampled cows excreted by one shedding route
only, whereas 6.4% shed bacteria in the vaginal mucus,
feces, and milk simultaneously. A combined shedding in
vaginal mucus and in feces and in vaginal mucus and milk
were observed in 14.6% and 10% of cases, respectively
[92]. The study by Beaudeau et al. [122] reported, within
endemic infected dairy herds, that 85% of their infected
cows excreted by one shedding route only. In their study,
only 2% of the infected cows shed bacteria in the vaginal
mucus, feces and milk simultaneously. When combined
shedding occurred, the combination of shedding in vaginal
mucus and milk was the most frequently observed. The
results of these two French studies are very similar and the
slight diﬀerences observed could be due to diﬀerences in the
sampled population of cattle. Furthermore, diﬀerent areas
can have variable prevalence of Q fever and not only is
shedding in milk intermittent and its outset not associated
with parturition, but also it diﬀers from one herd to another
despite species being identical [97]. With milk being such
a major shedding route, bulk tank milk (BTM) samples are
useful for investigation of the sanitary grade of bovine [123],
ovine [124], and caprine herds [125]. Indeed, polymerase
chain reaction (PCR) and enzyme-linked immunosorbent
assay (ELISA) performed on BTM samples, in addition
to the analysis of serum samples of at least 10% of the
animals in the herd, give rapid, economical, and valuable
information on the herd’s status [97, 126]. In cows’ milk,
Marrie [127] identiﬁed Coxiella burnetii f o ru pt o3 2 - m o n t h
postpartum. Vaginal and fecal bacterial discharges seem to
have a major impact on environmental contamination as a
result of practices at kidding and eﬄuent management [88,
97]. Indeed, the incidence of Q fever has been observed
to increase signiﬁcantly during the lambing period (winter
and early spring) [9]. A seasonal correlation with spread of
goat manure was reported in The Netherlands during the
outbreaks of 2007-2008 [114].
Epidemiological data has shown that cows are more fre-
quently chronically infected than sheep with persistent shed-
ding of bacteria as a result [89]. The sites of chronic Coxiella
burnetii infection are the uterus and the mammary glands
of females [20, 24] .M o r e o v e r ,h e i f e r sa r el e s sf r e q u e n t l y
infected than older animals even in infected herds [128, 129]
making those a preferential group for eﬀective vaccination
programs.
4.2.2. Goats. Numerous studies have suggested that epi-
zootics of Q fever in goats are related to outbreaks in humans
[99, 114, 130, 131]. Indeed, in many countries, goats are
the most common source of human infection due to their
extensive raising and close contact with humans [98].
Q fever in goats can induce pneumonia, abortions, still-
birth, and delivery of weak kids, the latter two clinical
signs being the most frequently observed [98, 99, 132].
Abortionsoccurprincipallynearingtheendofthepregnancy
[99]. The frequency of occurrence of Q fever abortions in
goats is more important than in sheep with up to 90% of
females being aﬀected [98] .M o r e o v e r ,as t u d yb yB e r r ie t
al. [98] reported that pregnancies subsequent to abortion
may not be carried to term. Similar to cattle, pregnant an-
imals are more susceptible to infection than nonpregnant
animals [98]. These animals also frequently develop chronic
infections with persistence of the bacteria in the uterus
and mammary glands [133]. Shedding of Coxiella burnetii
by infected goats is discontinuous [98, 99, 134–136]. In
naturally infected goats, shedding seemed to be limited to
the kidding season following infection [137]. However, an
experimental study performed by Berri et al. [98]r e p o r t e d
that infected animals can shed Coxiella during two successive
kidding seasons in vaginal mucus and milk. Moreover,
shedding in milk can be maintained for a long period [98,
136]. Milk has been considered the major route of bacteria
excretion for this species by several authors [97].
De Cremoux et al. [138] in their recent study on bacterial
shedding in vaginal mucus observed persistence of shedding
at the subsequent kidding season following a Q fever
outbreak despite a reduced number of clinical signs. Similar
to cattle, susceptible or na¨ ı v ea n i m a l sw e r em o r ec o m m o n
among kids than adults [139].
4.2.3. Sheep. Sheep have a predisposition for abortion sim-
ilar to goats [13, 98]. However, Q fever in sheep seldom
causes chronic infections [13, 17, 132]. Infected sheep, like
goats, shed Coxiella burnetii in vaginal secretions, urine and
feces, and to a lesser extent in milk [97]. In naturally infected
sheep, the bacterium has been isolated in vaginal discharges
long after abortion [140] and can be shed at subsequentInternational Journal of Microbiology 5
pregnancies [141]. In the study by Rodokalis et al. [97], no
ewe was found to shed bacteria constantly in milk. Some
sheep have been found to shed Coxiella burnetii during 11 to
18 days postpartum in feces [127]. Most ewes shed bacteria
byatleasttworoutes,mainlyinfecesandvaginalmucus[97].
Rodokalis et al. [97] reported a ﬂock where no ewe ever shed
by a single route (no exclusive shedding in milk or feces or
vaginal mucus).
In certain areas (e.g., Basque country), sheep are an im-
portant source of human infections. Garcia-P´ erez et al. [124]
studied the presence of Coxiella burnetii DNA in BTM and
its association with seroprevalence. The authors reported a
lower seroprevalence in lambs and yearlings compared to
older ewes. Herds with a history of abortion had a higher
seroprevalence than other herds, but the diﬀerence observed
was not signiﬁcant. Flocks with a level of seropositivity
superior to 30% were more frequently positive on BTM-PCR
analysis. However, ﬂocks with a low number of seropositive
animals but with a positive result at BTM-PCR analysis were
also observed in this study [124].
In France, two cases of human Q fever were associated
with the use of ovine manure as garden fertilizer. The ﬂock
of sheep that had provided the manure did not present any
clinical signs, despite the presence of seropositive animals
andexcretionofbacteriainfeces[101].TheQfeveroutbreak
that occurred in Bulgaria in 2004 was also associated with
infected sheep and goats [142].
Astobiza et al. [143]studiedtheeﬀectofvaccinationwith
a phase I inactivated vaccine (Coxevac). After vaccinating
50% of replacement lambs and 75% of ewes in two naturally
infected sheep ﬂocks, the number of abortions, shedders
and the general bacterial load were signiﬁcantly diminished.
However, this measure did not prevent seroconversion of
nonvaccinated lambs and identiﬁcation of Coxiella burnetii
in aerosols obtained in the sheep’s environment. This con-
ﬁrms that vaccination must thus be associated with other
preventive and control measures in infected environments.
4.2.4. Pigs. Natural susceptibility has been demonstrated by
the presence of antibodies to Coxiella burnetii in their serum
[144]. However, the role played by pigs in the epidemiology
of Q fever remains unknown [13].
4.2.5. Cats and Dogs. Dogs and cats can be infected by Q
fever and have been associated with human infections in
rural and urban areas [145–155]. In 1952, Gillepsie and
Baker [156] performed successful feline experimental in-
fections by subcutaneous inoculation, feeding infected yolk
sacs, and by contact with infected cats. Despite the presence
of pathogen in blood, urine, and a serological response,
clinical signs were not observed in all infected cats. In
felines, Q fever is, seemingly, frequently asymptomatic and
remainsundiagnosed.However,infectedcatsexcretebacteria
in the environment and become a potential source of human
infections. In Japan, cats are widely considered to be one of
the most important reservoirs of Coxiella burnetii [157]. The
study by Komiya et al. [157] found that seroprevalence was
signiﬁcantly higher in stray cats than in domestic cats. Thus,
the feline environment seems to inﬂuence the probability of
Coxiella infection [157].
The potential importance of dogs for the transmission of
Q fever to humans is rarely mentioned. Dogs are however as
close,if not closer, tohumans as cats.Dogs canpotentially be
infected by inhalation, tick bites, consumption of placentas,
or milk from infected ruminants. Buhariwalla et al. [148]
reported three human cases of Q fever associated with an
infectedparturientdog.Thepuppiesalldiedwithin24hours
of birth. Indeed, Q fever in parturient dogs has previously
been associated with early death of the pups [145]. Similar to
cats, a previous study on dogs in California reported a higher
prevalence of infection in stray than in domestic dogs [158].
Currently, the eﬀect of infection and its clinical presenta-
tion remain poorly investigated in felines and canines.
4.2.6. Horses. In previous studies, horses have been found
to be seropositive toward Q fever [158]. Indeed, the study
by Willeberg et al. [158] reported a seroprevalence of 26%
(31/121) in horses in California. To our knowledge, no
human case of Q fever has been associated with equids.
Moreover, Q fever is not investigated routinely in cases of
infertility or obstetric complications in this species.
4.2.7. Wild Animals. At present, wildlife is considered of
minor importance for Q fever epidemiology. Many wild
mammals and birds have been found to be hosts to the infec-
tious organism [13, 159–163]. A few cases of transmission
of Coxiella burnetii from wild animals to humans have been
reported but merit further experimental research [11, 13].
4.2.8. Ticks and Other Potential Vectors. Among ectopara-
sites, ticks are considered to be the natural primary reservoir
of Coxiella burnetii. Over 40 tick species are naturally
infected [39, 145, 163–171]. Experimental infections have
been obtained in guinea pigs with Ixodes holocyclus, Haema-
physalis bispinosa, Rhipicephalus sanguineus, and Dermacen-
tor andersoni.I nE u r o p e ,Ixodes ricinus is the most common
tick and Rhipicephalus sanguineus is frequent on dogs [102,
168, 170]. Thus, both these species of ticks could be (or
become) reservoirs of Coxiella burnetii in Europe.
Ticks excrete bacteria in saliva and feces. After multiply-
ing in the cells of the midgut and stomach of an infected tick,
extremely infectious bacteria are deposited onto the animal
skin during fecal excretion. The feces are extremely rich in
bacteria and may reach a concentration of 1012 organisms
per gram [20, 89]. Furthermore, transovarial transmission
is suspected as bacteria have been isolated in the ovaries of
infectedticks[20].However,despiteallthesefactors,ticksare
notthoughttocontributetothemaintenanceofcoxiellosisin
endemic areas [13, 17]. Moreover, in the study by Astobiza et
al.[162],noneoftheticksanalyzedwerepositivewhentested
by PCR despite the area being endemic for Q fever. Similarly,
in two recent studies in endemic areas, a low percentage of
Dermacentor spp. [172]a n dIxodes ricinus [173]w e r ef o u n d
to be infected. Nevertheless, ticks are suspected of having
a signiﬁcant role in the transmission of Coxiella burnetii
among wild vertebrates, especially rodents, lagomorphs, and6 International Journal of Microbiology
wild birds [20, 89, 174]. In addition, Hirai and To [13]
hypothesized that they could play a role for transmission
of Coxiella from infected wild animals to domestic naive
animals. Human infections through tick bites are rarely
reported. Sporadic isolations of Coxiella burnetii in chiggers,
lice, and ﬂies have been reported [164, 175, 176].
4.3. Q Fever in Humans. The main characteristic of Q fever
in humans is its clinical polymorphism [1, 15, 20] .Qf e v e r
is therefore considerably underdiagnosed and underreported
[177].Afteranincubationperiodof1to3weeks[33,107],Q
fevercancauseeitheranacuteorachronicdisease.Sizeofthe
inoculum, geographical area, route, and time of infection, as
well as host factors inﬂuence the duration of the incubation
period [15, 178, 179] and may contribute to the clinical
expression of acute or chronic infection [20, 127].
4.3.1. Acute Q Fever. In the acute form, infections can be
totally asymptomatic in 50 to 60% of cases or cause a
self-limiting illness associated with fever, fatigue, headache,
and myalgia (inﬂuenza-like syndrome). When clinically ex-
pressed, acute fever is frequently accompanied by atypical
pneumonia and/or hepatitis. Pneumonia is an important
manifestation of Q fever in humans [1, 15, 20]. It is
uncommon in Australia and some parts of Russia, whereas
in North America and Europe it is the major manifestation
of infection [93, 96]. Pneumonia is typically mild, but
progression to acute distress syndrome can occur [107, 180,
181]. Endocarditis can exceptionally be associated with acute
infection in 0.76% of cases [182, 183]. In pregnant woman,
Q fever can lead to spontaneous abortion, intrauterine
fetal death (IUFD), premature delivery, or intrauterine
growth retardation. Transplacental infection of the fetus in
utero has also been reported [109, 184, 185]. Moreover,
Carcopino et al. [186] found that Q fever was signiﬁcantly
associated with oligoamnios, which is a recognized cause of
neonatal morbidity and mortality [187, 188]. One case of
endocarditis has been reported in a pregnant women with
a bioprosthetic aortic valve and led to maternofetal death at
27-week gestation [186]. Infection during the ﬁrst trimester
of the pregnancy is particularly associated with a negative
outcome [185, 186]. After infection, breast feeding is of
course contraindicated [185].
Mortality rate of acute Q fever is estimated at 1 to 2%
[107, 114, 189]. Myocarditis, occurring in less than 1% of
cases, is the ﬁrst cause of death [190]. As yet, myocarditis has
n o tb e e nr e p o r t e di np r e g n a n tw o m e n[ 191].
4.3.2. Chronic Q Fever. Chronic Q fever consists in the per-
sistenceofinfectionformorethan6months.ChronicQfever
concerns 5% of infected individuals [192]. Most commonly,
endocarditis is observed in 60–70% of cases of chronic
infections [193], but chronic hepatitis, osteomyelitis, septic
arthritis, interstitial lung disease, chronic fatigue syndrome
[194], or infection of aneurysm and vascular grafts can
also occur [1, 15, 20]. Q fever-associated endocarditis has
been estimated to be responsible for 3 to 5% of all cases of
human endocarditis [182, 195]. Individuals with underly-
ing valvulopathy or other cardiovascular abnormalities are
predisposed to the development of endocarditis [182, 183].
Over recent years, the occurrence of rare clinical man-
ifestations such as osteomyelitis, optic neuritis, pericarditis,
lymphadenopathy, and Guillain-Barre has signiﬁcantly in-
creased. Meningitis, encephalitis, polyradiculoneuritis, pe-
ripheral neuropathy, cranial nerve deﬁciency, optic nevritis,
and paralysis of the oculomotor nerve have been reported
in 3.5% of infected patients. The main clinical signs in
neurological cases are headaches, behavioral problems, cog-
nitive deﬁciency, or confusion. Convulsions and even epilep-
tic ﬁts and aphasia are possible [196–198]. In pregnant
women,chronicQfevercanleadtospontaneousabortionsin
future pregnancies [109, 117, 199]. The prognosis of chronic
infections is less favorable than for acute infections [107].
Antibiotictreatmentislesseﬀective,andthediseaseisusually
long with mortality rates that can reach more than 50%
[107].
4.3.3. Q Fever in Children. In children, Q fever is thought to
be rare. This could be explained by frequent asymptomatic
or nonspeciﬁc presentations of infection leading to undi-
agnosed cases of Coxiella infection. Cases of hepatitis and
pneumonia have however been reported in children and
can be fatal [93, 200]. In Northern Ireland, McCaughey et
al. [201] reported a seropositivity rate inferior to 10% in
children. The seropositivity rate increased markedly during
the late teenage years and especially in young adults [201].
Increased exposure with age is a plausible hypothesis to
explain this phenomenon.
4.3.4. Postillness Followup. The study by Limonard et al.
[202] on followup of patients after the Q fever outbreak
in The Netherlands reported fatigue in 52% of patients
6 months after illness and in 26% one year after illness.
They observed very high level of anti-phase I and anti-phase
II antibodies up to 3 months after the onset of disease,
then a gradual decrease in the following 9 months. Post-
Q fever chronic fatigue syndrome has also been reported
[114, 194, 203]. This syndrome has been attributed to
dysregulation of cytokine production, induced by persistent
antigens including LPS and proteins, rather than persistent
latent Coxiella [203].
4.3.5. Predispositions. Recent experimental data indicates
that host factors rather than speciﬁc genetic bacterial deter-
minants are the main factors inﬂuencing the clinical course
of Coxiella burnetii infection [14, 47, 195, 204].
In humans, Q fever is mainly considered an occupational
hazard. A study by Whitney et al. [205] on 508 American
veterinarians reported a prevalence rate (22.2%) far superior
to the prevalence rate in the general adult US population.
Veterinarians from a mixed or large animal practice were
signiﬁcantly more likely to be seropositive than veterinarians
from a small animal practice. Furthermore, living on a farm,
in the past or present, increased the probability of being
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mask, occupational risks (accidental cuts and needle sticks),
and routine contact with water were also demonstrated
as signiﬁcant risk factors for infection [205]. McQuiston
and Childs [206] reported a seroprevalence of 7.8% among
American veterinarians, farmers, slaughterhouse workers,
and tannery workers. Furthermore, a Northern Irish study
reported a seropositivity rate signiﬁcantly higher among
farmers than in the general population (P<0.001) [201].
Seropositivity was found to be slightly, but signiﬁcantly,
higher in males than in females (P = 0.023). In The
Netherlands, during the Q fever outbreak in May 2010,
people living within 2km of the infected dairy goat farm had
a much higher risk for Q fever than those living more than
5kmaway[207].
On the contrary to countries where cats are the main res-
ervoir of Coxiella burnetii where no sex predisposition is re-
ported, men between 30 and 70 years of age are the most
frequently aﬀected by clinical Q fever in countries where
cattle are considered the main reservoir [208–214]. The
study by Raoult et al. [204] reported that being a male
and over the age of 15 increased the risk of symptomatic
disease. In Australia and France, males are 5-fold and 2.5-
fold more likely than females to develop disease, respectively
[195].Althoughtheprecisereasonforthisdiﬀerenceremains
unknown,ithasbeensuggestedthatsexhormonesplayarole
[195, 204] . Indeed, Leone et al. [215]r e p o r t e dap r o t e c t i v e
role of 17beta-oestradiol towards Q fever infection rendering
females more resistant. Surprisingly, in a comparative study
on clinical expression and outcome of Q fever after the out-
break in Chamonix Valley in France, pregnant women were
found to be signiﬁcantly less frequently symptomatic than
other women and other patients (9.1% of pregnant wom-
en were symptomatic versus 90.6% of men, 75% women,
and 33.3% children) [216]. Endocarditis is more frequently
observedinmenover40yearsofage[217].Immunocompro-
mised hosts are at risk of severe disease and of development
of chronic infection. Furthermore, people with heart valve
lesions, vascularabnormalities, liver cirrhosis, and cancerare
moresusceptibletodevelopingchronicQfever[183,218].In
the study by Carcopino et al. [186], 52.8% of the pregnant
women with acute Q fever developed chronic serologic
proﬁles.
4.3.6. Treatment. In nonpregnant women and other patients
with acute Q fever, treatment consists in a daily dose of
200mg doxycycline for 14 to 21 days. Hydroxychloroquine
can be associated with doxycycline. Hydroxychloroquine
increases the pH of the phagolysosomes, and its associa-
tion with doxycycline has a bactericidal eﬀect [219, 220].
Rifampin, erythromycin, clarithromycin, and roxithromycin
can also be used as an alternative treatment [221, 222]. Flu-
oroquinolones are recommended in cases of meningoen-
cephalitisastheirpenetrationintothecentralnervoussystem
is better compared to doxycycline. As mentioned previously,
treatment with IFNγ has proven eﬀective in certain cases
[71, 72].
Treatment of chronically infected patients consists in a
daily dose of 200mg of doxycycline associated with 600mg
of hydroxychloroquine for duration of 18 to 36 months. The
dosage of hydroxychloroquine is adjusted three months after
initiation of treatment to obtain a plasmatic level of 1 ±
0.2mg/L [219]. During the treatment, an ophthalmologic
followup is recommended every 6 months to detect accumu-
lationofhydroxychloroquineintheretina.Rolainetal.[223]
advised a plasmatic concentration of 5mg/L of doxycycline
for eﬀective treatment. Minimal inhibition concentration
(MIC) for doxycycline against Coxiella burnetii varies from
1t o4μg/mL [220]. Bacterial resistance to doxycycline was
observed by Rolain et al. [224, 225] in a patient with en-
docarditis. Thus, serological testing on a regular basis to
evaluate response to treatment is advised. It is considered
that an anti-phase I IgG titer inferior to 200 is predictive of a
clinicalcure[226].Adecreaseof2dilutionsinantibodytiters
in one year at the minimum signiﬁes successful evolution
[220].
In infected pregnant women, administration of long-
term cotrimoxazole (320mg trimethoprim and 1600mg sul-
famethoxazole for at least 5 weeks), a bacteriostatic antibi-
otic, is advised [186]. After delivery, a daily treatment with
200mg of doxycycline associated with 600mg of hydrox-
ychloroquine for 1 year minimum is advised for chronically
infected women. The study by Carcopino et al. [186]r e -
ported that long-term cotrimoxazole therapy signiﬁcantly
reduced the number of obstetric complications, the fre-
quency of placentitis, and the development of a chronic
serological proﬁle. In their study, no IUFD was observed
in treated women (0% versus 27% of IUFD in nontreated
women). The complications reported were intrauterine
growth retardation and premature delivery. No spontaneous
abortions and no oligoamnios occurred [186].
4.3.7. Animal Models for Human Q Fever. Animal models
for human infection are commonly laboratory mice and
guinea pig models. Guinea pigs are regarded as a model
of acute Q fever in humans [227]. On the contrary to
guinea pigs, mice develop a chronic infection, although
endocarditis does not occur in normal adult mice. They
remain chronically infected for months and excrete bacteria
in feces and urine. Their susceptibility to infection varies
in function of the mouse strain [228]. Extrapolations of
observations on experimentally infected laboratory rodents
to naturally infected humans could prove erroneous in some
aspects, and caution is recommended. Gonder et al. [229]
and Waag et al. [230] reported a successful infection by
aerosol route in cynomolgus and rhesus macaques. After
infection, the macaques developed fever and pneumonia
after 4 to 7 days. Their clinical expression of Q fever is thus
unsurprisingly the closest to human clinical expression.
4.3.8. Outbreak in The Netherlands. In 2009, infected goats
were at the origin of 2,361 human cases of Q fever (including
six deaths) diagnosed in The Netherlands [231]. Most cases
were diagnosed in the North Brabant Province. A recent
increase in high intensity dairy goat farming has lead to
development of very large densely populated farms: from
100,000 goats in 2000 to 230,000 goats on approximately
350 farms in 2009 [232]. Transport of animals, manure8 International Journal of Microbiology
spreading, and wind have been reported as inﬂuential factors
for human infections. In a study by Karagiannis et al.
[233] on the outbreak in 2007 in The Netherlands, living
east of the area in which a positive goat farm, cattle,
or small ruminants were situated, smoking and contact
with agriculture products were found to be associated with
recent infection. Scientists suspected the emergence of a
more virulent subtype of Coxiella burnetii than the initial
subtype of bacterium identiﬁed [131, 231]. Genomic studies
reportedthatmultiplegenotypeswereinvolvedintheQfever
outbreak. However, an identical subtype was identiﬁed in
a dairy goat herd suﬀering from multiple abortions and in
several human patients [131]. This particular subtype could
thus have a survival and propagation advantage compared
to other bacterial subtypes [131, 231]. Roest et al. [234]
performedmultiplelocusvariabletandemrepeatanalyseson
a large number of Q fever positive samples originating from
domestic ruminants and associated with the outbreak. Their
study found that one genotype predominated on all dairy
goat farms in the southern part of The Netherlands. Indeed,
on 12 out of 14 dairy goat farms, this genotype was found
in 91% of samples, varying from 33% to 100%. Nine other
genotypes occurred once, each representing only 0.8% of all
found genotypes on the farms. The predominant genotype
was found on 11 farms in the southern Netherlands and
on a farm in the eastern part of the country. This suggests
a clonal spread of Coxiella burnetii with this predominant
genotype. However, another study by Huijmans et al. [235]
found ﬁve distinct genotypes (3 in humans and 4 in
livestock) implicated in the outbreak and concluded that
environmental factors such as animal and human density
and climate, rather than one particularly virulent strain
favored the Dutch outbreak and its spread. Control measures
were put in place following the outbreak. Vaccination of
goats with Coxevac vaccine on voluntary grounds began
in 2008. Vaccination was exclusively performed in areas
of the human outbreak. In 2009, vaccination of all dairy
sheep and goats on farms with more than 50 animals be-
came mandatory, and area of vaccination was enlarged
(North-Brabant province and parts of adjacent provinces).
Moreover, BTM testing was performed every two weeks.
A farm was considered infected when 2 consecutive BTM
samples were positive by PCR. Movement and breeding were
banned for dairy goats and sheep on infected farms [236].
Moreover, culling of all pregnant goats and sheep on these
farms was also in application until May 2010.
5.Diagnosis
5.1. Direct Diagnosis. Direct diagnostic methods identify the
presence of the bacterium or of one of its components.
5.1.1. Coloration and Direct Visualization. Direct visualiza-
tion of Coxiella burnetii on smears or frozen tissue is a
method of Q fever diagnosis. Smears are taken from the pla-
centa of aborted ruminants, from the fetus stomach content,
or from other body tissues. Coxiella burnetii does not stain
reliably with Gram stain, and Gimenez stain is preferentially
used [237]. A Stamp-Macchiavello coloration, commonly
called Macc staining, or routine Giemsa stain can also be
performed. The speciﬁcity and sensitivity of direct vis-
ualization by bacterioscopic examination is poor, due to
possible confusion with other pathogens such as Brucella
spp., Chlamydophila spp., or Chlamydia spp.[ 92].
5.1.2. Immunohistochemistry (IHC). IHC has been per-
formed for the diagnosis of chronic cases of Q fever. It can
be utilized for detection of Coxiella burnetii in tissues ﬁxed
in paraﬃn or acetone smears [238]. Dilbeck and McElwain
[239] developed an avidin-biotin-peroxidase complex IHC
staining method for diagnosis and routine screening of ovine
and caprine placental tissues after abortion. This technique
is rapid and does not necessitate live bacteria or fresh tissues
for diagnosis. Furthermore, it renders retrospective studies
on stored samples possible. However, IHC is not useful for
large-scale epidemiological studies.
5.1.3. Bacterial Culture. In vitro cell culture of the bacteria
is the gold standard for diagnosis of bacterial infections.
Coxiella burnetii can be cultured eﬃciently in the yolk sac
of chicken embryos and also on diverse cellular specimens,
such as human embryonic lung ﬁbroblasts, mosquito cells,
green monkey kidney (Vero) cells, L cells, tick tissue cultures,
and so forth [24]. However, technically, culture of Coxiella
burnetii remains a diﬃcult process and sensitivity of this
diagnostic method is low. Recently, Coxiella burnetii can
be grown outside a host cell in a cell-free laboratory
medium [240]. The latter cell-free medium has a compo-
sition that strictly corresponds to the organism’s metabolic
requirements in the phagolysosome (in vivo Coxiella is
strictly intracellular). This ﬁnding is revolutionary and will
permit further studies on Coxiella burnetii. Another practical
limitation to bacterial isolation is that it requires a Biosafety
Laboratory 3 because of its high infectivity. As a result,
culture is rarely performed, especially in veterinary medicine
[192]. Moreover, epidemiological studies based on bacterial
isolation are not practical.
5.1.4. Polymerase Chain Reaction (PCR). PCR oﬀers sub-
stantial beneﬁts for the identiﬁcation of Coxiella burnetii
compared to other laboratory techniques, especially in the
early clinical stages of the illness [241, 242]. It has been
successful in detecting Coxiella burnetii DNA in various
samples, including cell cultures, biopsy samples, blood,
arthropods, and serum samples [193, 243].Its sensitivity and
speciﬁcity are high. However, the usefulness of conventional
PCR is limited by its inability to quantify the bacteria
present. The development of real-time quantitative PCR
(RTq PCR) not only renders PCR a rapid diagnostic tool
but also provides quantiﬁable information. RTq PCR can
be automated and thus can be used in large-scale studies.
The qualities of PCR make it very useful for early diagnosis
of infection during the period when antibodies are not yet
present [242]. Several primers are available for diagnosis
[241, 244–246]. A primer originating from the frequently
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is commonly used and has proven to allow very sensitive
testing [241, 246]. In a study by Schneeberger et al. [246],
Coxiella burnetii DNA was detected in 98% of seronegative
acute Q fever patients and in 90% of anti-phase 2 IgM
seropositive patients. PCR became progressively negative as
the serological response developed [246]. Hou et al. [247]
noticed a signiﬁcant association between the absence of
IgM antibodies and a positive PCR result. Negative serology
was most frequent in Q fever cases where sampling had
been performed within the two weeks of illness. In such
cases, the authors recommend routine PCR testing as well
as serology. When PCR was included in the diagnostic
procedure primarily based on serology, a marked increase
of sensitivity was observed (78% versus 29% when serology
was used as unique diagnostic method) [247]. PCR and RTq
PCRareconsideredmethodsofchoicefortheDNAdetection
in diverse samples [122]. However, PCR and RTq PCR are
incapable of distinguishing bacterial DNA from live and/or
dead bacteria [248]. The advantage is that sampled tissues
can be frozen, put into formalin, or ﬁxed with paraﬃn[ 242].
The disadvantage is that interpretation of positive results
in fresh samples can be diﬃcult [107, 249]. PCR kits are
gradually becoming available [250]. Analysis of samples by
PCR should be performed on sampling day to minimize the
risk of obtaining false-negative results. Indeed, the study by
Guatteo et al. [90] reported that only two-thirds of milk and
one-half of vaginal mucus samples that were initially positive
on the day of sampling remained positive after storage at
−20◦C during three days. Samples found to be persistently
positive had a signiﬁcantly higher estimated initial bacterial
titre than those which became negative after storage.
5.2. Indirect Diagnosis. Indirect diagnostic methods identify
speciﬁchumoralorcellularimmunityinresponseto Coxiella
burnetii infection. The diagnostic methods available in
human and veterinary medicine diﬀer, and little informa-
tion is available concerning epidemiological sensitivity and
speciﬁcity of diagnostic methods, especially in ruminants
(Table 1).
5.2.1. Complement Fixation Test (CFT). In veterinary med-
icine, CFT was the method of reference for serological
diagnosis according to OIE [102, 255, 256]. CFT usually
utilizes phase 2 antigens only [27, 102]. It is capable of
detecting approximately 65% of infected subjects during
the second week after initial clinical signs and 90% during
the fourth week [49]. CFT is more laborious, less speciﬁc,
and less sensitive than indirect immunoﬂuorescence assay
(IFA) [192] or ELISA (described hereafter) [192]. A study by
Rousset et al. [257] on goats originating from diﬀerent herds
reported that CFT results obtained on sera of aborting goats
and of nonaborting goats were not signiﬁcantly diﬀerent and
conﬁrmed the lack of sensitivity of CFT compared to ELISA.
CFT, on the contrary to ELISA, is incapable of detecting
all IgG subclasses. In ruminants, only IgG1 ﬁxes the com-
plement and can thus be detected by CFT. Moreover, IgG2,
IgM and anticomplement substances potentially present in
sera are capable of interfering with ﬁxation of IgG1 to the
complement lowering the titer of IgG1 detected by CFT [99].
Rousset et al. [257] advised not to use CFT for serological
animal screening because of its low sensitivity.
5.2.2. Enzyme-Linked Immunosorbent Assay (ELISA). An-
other method of diagnosis for human and animal cases is
ELISA. This method is more sensitive and easier to perform,
and to standardize than CFT [192]. Moreover, a strong
association was reported between strongly positive ELISA
results and the occurrence of abortion in goats [257]. As
mentioned above, the higher sensitivity of ELISA compared
to CFT could be due to the detection of the IgG2 subclass
of antibodies, which are incapable of binding to the guinea
pig complement [27]. Commercially available human ELISA
kits are frequently coated by phase 1 and phase 2 antigens.
The antigens present are of two possible origins: antigens
of the American Nine Mile strain of Coxiella burnetii
isolated from an endogenous tick or antigens of a strain
originating from infected European domestic ruminants.
ELISA kits coated by the latter antigens are more sensitive
and are advised for serological diagnosis [258]. In France,
the ELISAs available for veterinary diagnostic purposes do
notdiﬀerentiateanti-phase1andanti-phase2antibodiesbut
detects total antibodies [102]. ELISA tests can be automated
which facilitates large-scale studies [257].
In the study by Guatt´ eo et al. [126], persistent shedder
cows had mainly a persistently highly seropositive status
(20 out of 27 and 17 out of 23 for weekly and monthly
samplings, resp.) while these proportions were much lower
for the other shedding patterns. In addition, around 50%
of persistently highly seropositive cows were found to be
persistent shedders, while seropositive cows with other
patterns were mainly either non- or sporadic shedders.
5.2.3. Immunoﬂuorescence Assay (IFA). In human medicine,
IFAiscommonlyconsideredthereferencediagnostictestand
is the most frequently used worldwide [102]. It is accurate,
highly sensitive, and speciﬁc [192]. The study by Rousset et
al. [257] on goats demonstrated an overall good agreement
between IFA and ELISA results. The study also reported
that IFA results obtained on sera of aborting goats and
of nonaborting goats were signiﬁcantly diﬀerent and were
associated with occurrence of abortion [257]. Moreover, IFA
is capable of detecting the two antigenic variants of Coxiella
burnetii ( p h a s eIa n dp h a s eI I ) .A sm e n t i o n e dp r e v i o u s l y ,
in acute infections, anti-phase II antibodies are detected. In
chronic infections, anti-phase I and anti-phase II antibodies
are present but anti-phase I antibodies predominate [192].
As anti-phase II antibodies are present in all stages of
infection, screening for epidemiological purposes is based
on the detection of anti-phase II antibodies [257]. Cross-
reactions with Legionella micdadei and Bartonella have been
reported but do not cause any problem for the interpretation
of quantitative results [259, 260]. In human medicine, IFA
distinguishes IgG and IgM. Titers of anti-phase II IgG
superior or equal to 200 and of anti-phase II IgM superior or
equalto50correspondtoanacuteinfectionwithapredictive
value of 100%. An isolated high titer of IgM (≥50) can10 International Journal of Microbiology
Table 1: Relative epidemiological sensitivity and speciﬁcity (%) for diﬀerent diagnostic methods.
Method evaluated Method of reference Species Se Sp Reference
Agglutination MI1 Cattle 94.3 95.5 [251]
ELISA CF2 Human 99 88 [252]
ELISA IFI3 Human — 100 [253]
ELISA Clinical signs Human 94.8 — [254]
IFI Clinical signs Human 90.6 — [254]
CF Clinical signs Human 77.8 — [254]
CF IFI3 Human — 90 [252]
1MI: microimmunoﬂuorescence; 2CF: complement ﬁxation; 3IFI: indirecte immunoﬂuorescence.
correspond to the beginning of an acute infection as long as
the possibility of a false positive can be rejected. A chronic
infection is characterized by a high titer in anti-phase I IgG
(≥800) with a predictive value of 98% for a titer of 800 and
a predictive value of 100% for a titer of 1600 [261]. The
preferential use of IFA instead of CFT in veterinary medicine
would be advantageous for diagnosis and control of Q fever
at animal level [102]. IFA is currently the gold standard test
for serology.
5.2.4. Skin Test. A skin test method was proposed to in-
vestigate the cellular response and to improve detection of
infected cows at herd level [128]. The skin test consists in
an intradermal injection of extremely diluted inactivated
vaccine (Coxevac, CEVA-Sant´ eA n i m a l e ,L i b o u r n e ,F r a n c e ) .
The diluted vaccine induces an antigenic reaction. If the
animal has previously been infected by Q fever, a nodule of
variablesizewillappearatthesiteofinjection.Thistestcould
easily be applied by rural practitioners.
5.2.5. Negative Aspects of Indirect Diagnostic Methods. The
dependence of CFT, IFA, and ELISA on the presence of
antibodies limits their diagnostic value. Indeed, speciﬁc
antibodies are often absent during the ﬁrst 2 to 3 weeks
of infection, making early diagnosis by serology diﬃcult,
if not impossible [200]. In Q fever, phase II antibodies
can be detected within two weeks of infection in most
cases and within three weeks 90% are seropositive. AFSSA
[102] reports that a deﬁnitive diagnosis of human cases
by IFA can only be conﬁrmed one month and a half after
the initial clinical signs. Cellular immunity also necessi-
tates time before becoming detectable but the use of skin
testing at herd level prevents from it being a problem as
diﬀerent stages of infection are present simultaneously in
the herd. None of these tests are capable of conﬁrming
an etiological diagnosis at an individual level. Moreover, in
acute infections, rheumatic factor, anti-mitochondrial anti-
bodies, anti-nuclear antibodies, anti-smooth muscle anti-
bodies, anticardiolipin and lupus anticoagulant, and other
autoantibodies often present a marked increase in their
plasmatic levels and can interfere with diagnostic assays
[262]. A high prevalence of IgM against Epstein-Barr
virus, cytomegalovirus, parvovirus, Bordetella pertussis, and
Mycoplasma pneumonia has also been detected. Vardi et al.
[262] concluded that diagnosis should not rely on a unique
diagnostic approach. The global clinical and epidemiological
context must be taken into account as well as the limitations
of diagnostic assays. Bacteriological analyses are necessary to
conﬁrm or inﬁrm any suspicion of Q fever [257].
5.3. Diagnosis by Histopathology. In acute cases of hepatitis,
the presence of doughnut granulomas can be visualized in
histopathology hepatic specimens but they are not pathog-
nomonic of Q fever. However, in chronic infections, granu-
lomas are less organized but bacteria can be detected in large
vacuoles [192]. As mentioned above, in bovids, placentitis
wasfoundtobesigniﬁcantlyassociatedwithCoxiella burnetii
infection [119]. On microscopic examination, an increased
number of mononuclear cells (macrophages, lymphocytes,
and plasma cells) can be identiﬁed in the chorionic stroma.
Increased stromal collagen is also frequently observed.
Furthermore, placental necrosis is signiﬁcantly associated
with the presence of Coxiella burnetii. Chorionic epithelial
cells and villus tips are the most frequently aﬀected. Infected
trophoblasts are distended and contain basophilic granular
to foamy material. The cytoplasms of infected cells appear
bright red with the Macc stain, and their nuclei are
commonly eccentric. A modiﬁed Koster’s acid-fast (MAF)
staining of fresh placenta smears is considered a good
screening test, but conﬁrmation by immunohistochemical
techniques remains necessary [119]. In endocarditis lesions,
Coxiella burnetii is visible as a voluminous intracytoplasmic
mass within infected mononuclear cells [263].
6. Control Methods andVaccination
In the case of a Q fever outbreak, sanitary and prophylactic
measuresshouldbeappliedatherdandhumanlevel,inorder
to limit disease transmission. Human and animal infections
must be diagnosed early and treated immediately to prevent
the development of chronic infections and secondary com-
plications.WithQfeverbeingazoonosis,prophylaxisatherd
level is fundamental.
6.1. Control Methods. In The Netherlands, spread of manure
from infected herds is forbidden for at least 90 days after
suspicion of infection [130]. The eﬀectiveness of this mea-
sure must be evaluated and modiﬁed if necessary. Arricau-
Bouvery et al. [264] performed decontamination of feces
of experimentally infected goats with calcium Cyanamid.International Journal of Microbiology 11
Based on the results of this study, adding 0.5% of calcium
Cyanamid to contaminated dung is an eﬀective disinfectant.
This measure, or its modiﬁed equivalent, should be applied
worldwide if its eﬀectiveness is proven. Transport of animals
in and from infected areas should be strictly controlled and
restricted to days without wind.
In France, when Q fever has been diagnosed in a herd on
a cheese-producing farm, milk of the aborted females must
be discarded. Indeed, sale, transformation, and treatment
of this milk are strictly forbidden (AFSSA, 2007). Milk of
the remainder of the ﬂock can be used for transformation,
unless it is highly suspected that dairy products originating
from these animals are dangerous for human consumption.
In the latter case, the milk must be pasteurized at 72◦C
during 15 minutes or by an equivalent thermal treatment
[265] (AFSSA, 2007). If Q fever is diagnosed on a farm
producing raw milk for direct human consumption, sale of
milk is forbidden during one year after the initial diagnosis
of Q fever in an animal (AFSSA, 2007).
In the UK, Health Protection Agency guidelines suggest
the use of 2% formaldehyde, 1% Lysol, 5% hydrogen
peroxide, 70% ethanol, or 5% chloroform for decontam-
ination of surfaces, and spills of contaminated materi-
al should be dealt with immediately using hypochlorite,
5% peroxide, or phenol-based solutions (Health Pro-
tection Agency, 2010 at http://www.hpa.org.uk/deliberate
accidental releases/biological). However, the guidelines
note than decontaminating a large surface area is impossible.
Moreover,ScottandWilliams[266]foundthatformaldehyde
vapour was ineﬀective in the absence of a high relative
humidity. High-risk material (contaminated bedding, pla-
centa, and aborted fetuses) should be buried with lime or
incinerated. Treatment of manure with lime or calcium
cyanide is also recommended before spreading, and spread-
ing must be performed on a calm day.
At human level, prevention of exposure to animals or
wearing gloves and masks during manipulation of animals
or their litter is advised [102, 205]. Postexposure prophylaxis
guidelines for the general population have been established
in the USA [267, 268]. Doxycycline at a dose of 100mg a
day or 500mg of tetracycline twice daily started 8–12 days
afterexposureisadvised.Norecommendationisavailablefor
pregnant womenalthough cotrimoxazole hasbeen suggested
[267, 268].
Identiﬁcation of an antibiotic capable of severely dimin-
ishing or completely stopping shedding would radically
modify the management of Coxiella infection at a herd
level. Currently, antibiotic treatment does not stop shedding
[269, 270]. It could also prove useful to prevent infection
of pregnant women by inhibiting shedding of bacteria by
domestic cats and dogs.
Pasteurization of all milk products should be performed
if ingestion is proven an eﬀective route of infection and
afterdeterminationoftheminimalinfectingdoseofbacteria.
Awaiting further scientiﬁc research, caution is recommended
especially for individuals at high risk of chronic infection.
6.2. Vaccination. Rodokalis et al. [97] suggested a followup
of bovine and caprine herds by BTM analysis. In herds
presenting a PCR-positive BTM result, pools of 10 individual
milk samples should be tested by PCR to identify the shed-
ding animals. If shedders are not very numerous, they can
be eliminated and the other animals should be vaccinated.
Rodokalis et al. [97] also suggested vaccination of herds in
the proximity of infected herds or ﬂocks.
In animals, vaccines considered the most eﬀective are
composedofinactivatedwholephase1bacteria[49].Indeed,
in goats, the inactivated phase I vaccine (Coxevac, CEVA-
Sant´ e Animale, Libourne, France) protects eﬃciently against
abortion and has been shown to prevent bacterial shedding
in vaginal mucus, feces, and particularly in milk. However,
vaccination proved more eﬀective in nulliparous animals
than in parous animals. Furthermore, vaccination did not
clear infection in previously infected goats [135, 236, 271]
and cattle [272].
The study by Guatteo et al. [128, 272] on dairy cattle re-
ported that the probability of becoming a shedder for
vaccinated na¨ ıve nonpregnant bovids was 5-fold inferior to
theprobabilityforna¨ ıvebovidsreceivingaplacebo.However,
vaccination had no eﬀect on the bacterial load shed. Vacci-
nation of previously infected animals and of na¨ ıve animals
during pregnancy proved ineﬀective. Guatteo et al. [128,
272] hypothesized that the immunodepression induced by
pregnancy was responsible for the lack of eﬀective immune
response after vaccination. This explanation seems plausible,
but a second study is necessary to reach conﬁrmation of
this hypothesis. No adverse eﬀect was observed at the site
of injection in this study. One abortion was reported in a
vaccinated infected cow, but no further investigations were
performedonthisanimalexceptforaPCRonvaginalmucus
at abortion time that gave a negative result.
The major problem associated with vaccination with in-
activated phase 1 vaccine is the impossibility of distinguish-
ing vaccinated and naturally infected animals using ELISA
methods.Atherdlevel,theeﬀectivenessofavaccinationpro-
gram could be evaluated by monitoring bacterial shedding
in BTM. Currently, prophylaxis includes vaccination with
the nonfully licensed inactivated phase I vaccine, Coxevac
(CEVA-Sant´ e Animale, Libourne, France), when a focus of Q
fever is declared. This vaccine contains formalin-inactivated
Coxiella burnetii (strain RSA 493/Nine Mile phase I) [273]. A
r e c e n ts t u d yb yH e rm a n seta l .[ 274] reported the presence of
bacterial DNA originating from the Coxevax vaccine in goat
milk after inoculation. Coxiella burnetii DNA was detectable
until 9 days after vaccination in quantities estimated by
PCR up to approximately 100 genome equivalents per ml.
The quantity of DNA detected in their study was around
detection level. After the booster, the duration of vaccine-
derived DNA excretion was shorter, quantitatively lower, and
detectable in fewer animals than after the ﬁrst inoculation.
This ﬁnding induced the modiﬁcation of the Dutch control
strategy. Indeed, after the outbreak, testing BTM by PCR
on dairy farms with at least 50 sheep or goats every two
weeks and vaccination of all dairy goats and sheep with
Coxevac became compulsory. After this study, a two-week
interval between vaccination and BTM testing was imposed
[274]. The study by De Cremoux et al. [139] demonstrated
that vaccination in infected goat herds diminished clinical12 International Journal of Microbiology
signs and overall vaginal shedding with vaccination being
most eﬀective in young susceptible animals. In addition, the
duration of vaccine protection is not fully investigated. New
vaccines, such as recombinant vaccines, have been developed
[76].Severalofthesevaccineshaveproventobeantigenicbut
nonprotective. Others still require an investigation of their
eﬀectiveness in ﬁeld conditions [275]. An inactivated phase
II vaccine, Chlamyvax FQ, has also been tested on animals
but has failed to be eﬀective [135].
Vaccination of humans against Q fever could be eﬀective
in certain areas. Several diﬀerent vaccines have been devel-
oped since the discovery of Coxiella burnetii. In the Soviet
Union in the 1960s, a live attenuated strain M-44 obtained
after repeated passage through guinea pigs and mice was
used extensively for vaccination. Because of the long-term
persistence of the attenuated bacteria in animals and vacci-
nated human, this vaccine was never used in the West [276].
The Americans developed a chloroform-methanol residue
vaccine based on the phase I Henzerling strain of Coxiella
burnetii [277]. Despite being eﬀective in protecting animals
against aerosol challenges, humans were found to develop
severe reactions to vaccination [277]. A trichloroacetic acid
extract of phase I Nine Mile strain which comprised proteins
and LPS was also used for vaccination. However, Kazar et al.
[278] reported severe reactions in response to vaccination
in humans. Vaccinating with phase I Nine Mile extracts
treated with chloroform-methanol prevented severe reac-
tions, but the loss of protective immunogenicity rendered
these vaccines ineﬀective [279–282]. Currently, a formalin-
killed whole-cell vaccine prepared from phase I Henzerling
strain of Coxiella burnetii (Qvax, CSL Limited, Parkville,
Victoria, Australia) is licensed in Australia [49]. This vaccine
proved eﬀective in several studies [283], but vaccination is
only possible for individuals that have not previously been
in contact with Coxiella burnetii to prevent serious reactions
[17, 49, 284]. Screening is thus required before vaccination
[285, 286], making this preventive measure time consuming
and costly. Gefenaite et al. [287] performed a meta-analysis
of previous studies on the eﬀectiveness of Qvax vaccine. All
the studies included in their analysis reported a protective
eﬀect of vaccination (average eﬀectiveness after pooling raw
data:97%,CI:94–99%).However,severalbiaseswerepresent
in the latter studies. Gefenaite et al. [287] conclude that
generalization of the results to the general population or to
a speciﬁc risk group was not possible. The authors advised
more blinded, randomized, and unbiased research on Qvax
eﬀectiveness. Development of recombinant protein subunit
vaccines has proven disappointing [76, 288–290]. Before
initiating avaccinationprogram,epidemiologicalknowledge
of the area is necessary. Indeed, in endemic regions, vac-
cination is impossible for practical reasons (screening) and
noneﬀe c t i v ea sap r e v e n t i v em e a s u r e .H o w e v e r ,v a c c i n a t i o n
could be beneﬁcial for at-risk individuals such as pregnant
orimmunocompromisedindividuals,farmers,veterinarians,
abattoir workers, and research and reference laboratory
personnel in contact with Coxiella burnetii [49]. Availability
of vaccines causes a real problem in most countries and
vaccination is currently not performed in Europe.
7. Perspectivesfor the Future
A better knowledge of Q fever would improve diagnostic
procedures, control, and prevention of the disease in the
future.
A better understanding of the bacterium and of its
pathogenesis (entry into the cell, “sporulation-like” phe-
nomenon, metabolism, mechanism of resistance to acidic
conditions, infectivity of the bacterium, survival time in the
environment under diﬀerent management practices, etc.) is
essential. The immune response of the infected host must
also be investigated further. The risk factors for illness must
be determined (infectious dose, potential danger linked to
pets or not, etc.). Moreover, studies are required to deﬁne
more precisely the incidence, clinical spectrum, treatment,
morbidity, and mortality associated with Q fever in children.
Further studies on risk factors could conﬁrm or contradict
results of previous studies, such as the studies by Whitney
et al. [205] and McCaughey et al. [201]. Oral transmission
of Q fever remains a controversial subject to this day. Further
researchisessentialfortheestablishmentofguidelinesincase
of an epidemic. Importantly, a high standard of laboratory
diagnostic methods should be available in all accredited
laboratories and a systematic search for Coxiella burnetii
should be performed when clinical signs render the indi-
vidual or animal suspected of Q fever. New guidelines for
generalpractitioners and gynecologists should be established
to increase the rapidity of diagnosis of clinical Q fever.
Moreover, guidelines for prevention of infection of the
medical staﬀ and for prevention of transmission from one
patient to another are necessary. The veterinary aspects of Q
feveralso necessitatefurtherinvestigations. Indeed, theeﬀect
of antibiotic treatment on shedding of bacteria in rumi-
nants has been insuﬃciently studied. Antibiotics have been
suggested to diminish shedding by infected female animals
but the eﬀectiveness of this measure remains hypothetical.
The prevalence and potential clinical consequences of Q
fever in pets, wildlife, and other neglected domestic animals,
such as pigs, must also be investigated. Veterinarians must
include Q fever in their diﬀerential diagnoses of clinical cases
whenever it cannot systematically be rejected as a potential
diagnosis.Inactivewhole-cellphaseIvaccineshaveprovedto
be eﬀective but present several limitations (e.g., eﬀectiveness
may not be observed in the short term, current impossibility
of distinguishing vaccinated and naturally infected animals).
Further research in this ﬁeld and the development of new
recombinant vaccines would permit a better management of
fociofinfectionataherdlevelbutalsoinhumanpopulations
in the future. Animal vaccination and vaccination of individ-
uals at high risk of exposure or/and of severe clinical disease
would diminish signiﬁcantly the zoonotic risk.
8. Conclusions
Q fever is an underestimated disease that remains poorly
understood to this day. The lack of awareness of this disease
leads to underdiagnosing and underreporting of Q fever
cases. Q fever is ubiquitous, and the potential hosts for
the infectious bacteria are extremely numerous. Q feverInternational Journal of Microbiology 13
infections can have a signiﬁcant economical impact on
animal reproduction, animal trade, and the production and
commercialization of animal products. In small ruminant
ﬂocks, the consequences of Q fever can be disastrous. Its
zoonotic potential renders Q fever even more important.
Human infections can lead to death. Furthermore, with the
advances in human medicine, the number of immunosup-
pressed, premature, elderly, and chronically ill individuals
has greatly increased compared to several years ago. Thus,
the population predisposed to infection, and especially to
chronic infection, has also greatly increased. Chronic infec-
tions can lead to severe consequences that necessitate intense
medical treatment increasing public health costs and the
patients’ suﬀering. An early diagnosis and early initiation of
treatment are essential to improve prognosis by preventing
the development of a chronic infection or other potential
complications associated with coxiellosis.
Acknowledgments
This work was supported by the Federal Public Service of
Health, Food Chain Safety and Environment (Contract RF
11/6). Dr. S. R. Porter was funded by a research grant of the
University of Liege (Belgium).
References
[1] E. H. Derrick, “Q fever, a new fever entity: clinical features,
diagnosis and laboratory investigation,” The Medical Journal
of Australia, vol. 2, pp. 281–299, 1937.
[2] K. Alibek, T h eC h i l l i n gT r u eS t o r yo ft h eL a r g e s tC o v e r tB i o -
logical Weapons Program in the World,R a n d o mH o u s e ,N e w
York, NY, USA, 1999.
[3] E. Angelakis and D. Raoult, “Q fever,” Veterinary Microbiol-
ogy, vol. 140, no. 3-4, pp. 297–309, 2010.
[4] B. P. Marmion and M. G. P. Stoker, “Q fever in Great Britain:
epidemiology of an outbreak,” The Lancet, vol. 256, no. 6639,
pp. 611–616, 1950.
[5] R. Davoli and L. F. Signorini, “Antibodies against Rickettsia
burneti in serum of animals at a slaughter house in Tuscany.
VI,” Annali Della Sanit` a Pubblica, vol. 12, no. 1, pp. 67–73,
1951.
[6] G. Slavin, “‘Q’ fever: the domestic animal as a source of in-
fection for man,” Veterinary Record, vol. 64, article 743, 1952.
[7] B.P.Marmion,“QfeverII.Naturalhistoryandepidemiology
of q fever in man,” TransactionsoftheRoyalSocietyofTropical
Medicine and Hygiene, vol. 48, no. 3, pp. 197–207, 1954.
[8] G. Blanc and J.s Bruneau, “Etude ´ epid´ emio-´ ecologique dans
la forˆ et de Neﬁﬁk. 1-Pr´ esence chez le lapin de garenne et ses
arthropodes piqueurs de virus pathog` enes pour l’homme,”
Archives de l’Institut Pasteur du Maroc, vol. 5, pp. 87–200,
1956.
[ 9 ] A .D .E v a n s ,“ Qf e v e ri nS o u t hW a l e s , ”Monthly Bulletin of the
Ministry of Health and the Public Health Laboratory Service,
vol. 15, pp. 215–219, 1956.
[10] P. Fiset, “Phase variation of Rickettsia (Coxiella) burneti;
study of the antibody response in guinea pigs and rabbits,”
Canadian Journal of Microbiology, vol. 3, no. 3, pp. 435–445,
1957.
[11] L. Syrucek and K. Raska, “Q fever in domestic and wild
birds,” Bulletin—World Health Organization, vol. 15, pp.
329–337, 1956.
[12] M.G.StokerandB.P.Marmion,“ThespreadofQfeverfrom
animals to man; the natural history of a rickettsial disease,”
Bulletin of the World Health Organization, vol. 13, no. 5, pp.
781–806, 1955.
[13] K. Hirai and H. To, “Advances in the understanding of Cox-
iellaburnetiiinfectioninJapan,”JournalofVeterinaryMedical
Science, vol. 60, no. 7, pp. 781–790, 1998.
[14] EFSA, “Development of harmonized schemes for the moni-
toring and reporting of Q-fever in animals in the European
Union,” Tech. Rep. EFSA-Q-2009-00511, 2010.
[15] A. S. Benenson and W. D. Tigertt, “Studies on Q fever in
man,” Transactions of the Association of American Physicians,
vol. 69, pp. 98–104, 1956.
[16] R.Ormsbee,M.Peacock,andR.Gerloﬀ,“Limitsofrickettsial
infectivity,” Infection and Immunity, vol. 19, no. 1, pp. 239–
245, 1978.
[17] E. Rousset, V. Duquesne, P. Russo, and R. Thi´ ery, “Fi` evre Q:
probl´ ematiques et risques sanitaires,” Bulletin de l’Academie
V e t e r i n a i r ed eF r a n c e, vol. 160, pp. 107–114, 2007.
[18] M. Pape, K. Mandraveli, M. Arvanitidou-Vagiona, P. Niko-
laidis, and S. Alexiou-Daniel, “Q fever in northern Greece:
epidemiological and clinical data from 58 acute and chronic
cases,” Clinical Microbiology and Infection, vol. 15, supple-
ment 2, pp. 150–151, 2009.
[19] S. E. Ransom and R. J. Huebner, “Studies on the resistance of
Coxiella burneti to physical and chemical agents,” American
Journal of Epidemiology, vol. 53, no. 1, pp. 110–119, 1951.
[20] B. Babudieri, “Q fever: a zoonosis,” Advances in Veterinary
Science, vol. 5, pp. 82–154, 1959.
[21] F. M. Burnet and M. Freeman, “Experimental studies on the
virus of “Q” fever,” R e v i e w so fI n f e c t i o u sD i s e a s e s , vol. 5, no.
4, pp. 800–808, 1983.
[22] E. Mitscherlich and E. H. Marth, “Bacteria and rickettsiae.
Important in human and animal health,” in Microbial
SurvivalintheEnvironment,E.MitscherlichandE.H.Marth,
Eds., pp. 148–156, Springer, New York, NY, USA, 1984.
[ 2 3 ]O .G .B a c a ,T .O .S c o t t ,E .T .A k p o r i a y e ,R .D e B l a s s i e ,a n d
H. A. Crissman, “Cell cycle distribution patterns and gener-
ation times of L929 ﬁbroblast cells persistently infected with
Coxiella burnetii,” Infection and Immunity,v o l .4 7 ,n o .2 ,p p .
366–369, 1985.
[24] O. G. Baca and D. Paretsky, “Q fever and Coxiella bur-
netii: a model for host-parasite interactions,” Microbiological
Reviews, vol. 47, no. 2, pp. 127–149, 1983.
[25] K. I. Amano and J. C. Williams, “Chemical and immunolog-
ical characterization of lipopolysaccharides from phase I and
phase II Coxiella burnetii,” Journal of Bacteriology, vol. 160,
no. 3, pp. 994–1002, 1984.
[26] A. Moos and T. Hackstadt, “Comparative virulence of
intra- and interstrain lipopolysaccharide variants of Coxiella
burnetii in the guinea pig model,” Infection and Immunity,
vol. 55, no. 5, pp. 1144–1150, 1987.
[27] B. Krt, “The inﬂuence of Coxiella burnetti phase I and phase
II antigens on the serological diagnosis of Q fever in cattle,”
Slovenian Veterinary Research, vol. 40, pp. 203–207, 2003.
[28] A. Setiyono, M. Ogawa, Y. Cai, S. Shiga, T. Kishimoto, and
I. Kurane, “New criteria for immunoﬂuorescence assay for Q
feverdiagnosisinJapan,”JournalofClinicalMicrobiology,vol.
43, no. 11, pp. 5555–5559, 2005.
[29] H. A. Thompson, T. A. Hoover, M. H. Vodkin, and E. I.
Shaw, “Do chromosomal deletions in the lipopolysaccharide14 International Journal of Microbiology
biosynthetic regions explain all cases of phase variation in
Coxiella burnetii strains? An update,” Annals of the New York
Academy of Sciences, vol. 990, pp. 664–670, 2003.
[30] T. A. Hoover, D. W. Culp, M. H. Vodkin, J. C. Williams,
andH.A.Thompson,“ChromosomalDNAdeletionsexplain
phenotypic characteristics of two antigenic variants, phase
II and RSA 514 (crazy), of the Coxiella burnetii Nine Mile
strain,” Infection and Immunity, vol. 70, no. 12, pp. 6726–
6733, 2002.
[31] A. M. Denison, R. F. Massung, and H. A. Thompson, “Anal-
ysis of the O-antigen biosynthesis regions of phase II isolates
of Coxiella burnetii,” FEMS Microbiology Letters, vol. 267, no.
1, pp. 102–107, 2007.
[ 3 2 ]R .S e s h a d r i ,I .T .P a u l s e n ,J .A .E i s e ne ta l . ,“ C o m p l e t eg e -
nome sequence of the Q-fever pathogen Coxiella burnetii,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 100, no. 9, pp. 5455–5460, 2003.
[33] M. Maurin and D. Raoult, “Q fever,” Clinical Microbiology
Reviews, vol. 12, no. 4, pp. 518–553, 1999.
[34] T. Masuzawa, K. Sawaki, H. Nagaoka, M. Akiyama, K. Hirai,
and Y. Yanagihara, “Determination of rickettsiae isolated in
Japan as Coxiella burnetii by 16S rRNA sequencing,” In-
ternational Journal of Systematic Bacteriology, vol. 47, pp.
883–884, 1997.
[35] M. Million, H. Lepidi, and D. Raoult, “Q fever: current di-
agnosis and treatment options,” Medecine et Maladies Infec-
tieuses, vol. 39, no. 2, pp. 82–94, 2009.
[36] H. G. Stoenner and D. B. Lackman, “The biologic properties
of Coxiella burnetii isolated from rodents collected in Utah,”
American Journal of Epidemiology, vol. 71, no. 1, pp. 45–51,
1960.
[37] H. Oda and K. Yoshiie, “Isolation of a Coxiella burnetii strain
that has low virulence for mice from a patient with acute Q
fever,”MicrobiologyandImmunology,vol.33,no.11,pp.969–
973, 1989.
[38] J. Kaz´ ar, M. Les´ y, P. Propper, D. Valkov´ a, and R. Brezina,
“Comparison of virulence for guinea pigs and mice of
diﬀerent Coxiella burnetii phase I strains,” Acta Virologica,
vol. 37, no. 6, pp. 437–448, 1993.
[39] T. Ho, K. K. Htwe, N. Yamasaki et al., “Isolation of Coxiella
burnetii from dairy cattle and ticks, and some characteristics
of the isolates in Japan,” Microbiology and Immunology, vol.
39, no. 9, pp. 663–671, 1995.
[40] T. Masuzawa, K. Sawaki, H. Nagaoka, M. Akiyama, K. Hirai,
and Y. Yanagihara, “Relationship between pathogenicity
of Coxiella burnetii isolates and gene sequences of the
macrophage infectivity potentiator (Cbmip and sensor-like
protein (qrsA),” FEMS Microbiology Letters, vol. 154, no. 2,
pp. 201–205, 1997.
[41] M. E. Frazier, L. P. Mallavia, J. E. Samuel, and O. G.
Baca, “DNA probes for the identiﬁcation of Coxiella burnetii
strains,” Annals of the New York Academy of Sciences, vol. 590,
pp. 445–458, 1990.
[42] J. E. Samuel, M. E. Frazier, M. L. E. Kahn, L. S. Thomashow,
and L. P. Mallavia, “Isolation and characterization of a
plasmid from phase 1 Coxiella burnetii,” Infection and
Immunity, vol. 41, pp. 448–493, 1983.
[43] L. P. Mallavia, “Genetics of rickettsiae,” European Journal of
Epidemiology, vol. 7, no. 3, pp. 213–221, 1991.
[44] D.Valkov´ aandJ.Kaz´ ar,“Anewplasmid(QpDV)commonto
Coxiella burnetii isolates associated with acute and chronic Q
fever,” FEMS Microbiology Letters, vol. 125, no. 2-3, pp. 275–
280, 1995.
[45] E. A. Savinelli and L. P. Mallavia, “Comparison of Coxiella
burnetii plasmids to homologous chromosomal sequences
present in a plasmidless endocarditis-causing isolate,” Annals
of the New York Academy of Sciences, vol. 590, pp. 523–533,
1990.
[46] O. Glazunova, V. Roux, O. Freylikman et al., “Coxiella bur-
netii genotyping,” Emerging Infectious Diseases,v o l .1 1 ,n o .8 ,
pp. 1211–1217, 2005.
[47] X. Yu and D. Raoult, “Serotyping Coxiella burnetii isolates
fromacuteandchronicQfeverpatientsbyusingmonoclonal
antibodies,” FEMS Microbiology Letters, vol. 117, no. 1, pp.
15–19, 1994.
[48] B. L. Scola, H. Lepidi, M. Maurin, and D. Raoult, “A guinea
pig model for Q fever endocarditis,” Journal of Infectious Dis-
eases, vol. 178, no. 1, pp. 278–281, 1998.
[49] OIE, “Manuel terrestre de l’OIE, Chapitre 2.2.10. Fi` evre Q,”
2005, pp. 433–445.
[50] T. Hackstadt and J. C. Williams, “Biochemical stratagem for
obligate parasitism of eukaryotic cells by Coxiella burnetii,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 78, no. 5 I, pp. 3240–3244, 1981.
[ 5 1 ]H .A .T h o m p s o n ,C .R .B o l t ,T .H o o v e r ,a n dJ .C .W i l l i a m s ,
“Induction of heat-shock proteins in Coxiella burnetii,”
AnnalsoftheNewYorkAcademyofSciences,vol. 590, pp. 127–
135, 1990.
[52] E. T. Akporiaye, J. D. Rowatt, A. A. Aragon, and O. G. Baca,
“Lysosomal response of a murine macrophage-like cell line
persistently infected with Coxiella burnetii,” Infection and
Immunity, vol. 40, no. 3, pp. 1155–1162, 1983.
[53] D. Raoult, M. Drancourt, and G. Vestris, “Bactericidal eﬀect
of doxycycline associated with lysosomotropic agents on
Coxiella burnetii in P388D1 cells,” Antimicrobial Agents and
Chemotherapy, vol. 34, no. 8, pp. 1512–1514, 1990.
[ 5 4 ]Y .Y .M o ,N .P .C i a n c i o t t o ,a n dL .P .M a l l a v i a ,“ M o l e c u l a r
cloning of a Coxiella burnetii gene encoding a macrophage
infectivity potentiator (Mip) analogue,” Microbiology, vol.
141, no. 11, pp. 2861–2871, 1995.
[55] E. T. Akporiaye and O. G. Baca, “Superoxide anion pro-
duction and superoxide dismutase and catalase activities in
Coxiella burnetii,” Journal of Bacteriology, vol. 154, no. 1, pp.
520–523, 1983.
[56] T. Redd and H. A. Thompson, “Secretion of proteins by
Coxiella burnetii,” Microbiology, vol. 141, no. 2, pp. 363–369,
1995.
[57] D. S. Zamboni and M. Rabinovitch, “Nitric oxide partially
controls Coxiella burnetii phase II infection in mouse pri-
mary macrophages,” Infection and Immunity, vol. 71, no. 3,
pp. 1225–1233, 2003.
[58] R. E. Brennan, K. Russell, G. Zhang, and J. E. Samuel,
“Both inducible nitric oxide synthase and NADPH oxidase
contribute to the control of virulent phase I Coxiella burnetii
infections,”Infection and Immunity,vol.72,no.11,pp.6666–
6675, 2004.
[ 5 9 ]J .H i l la n dJ .E .S a m u e l ,“ Coxiella burnetii acid phosphatase
inhibits the release of reactive oxygen intermediates in
polymorphonuclearleukocytes,”Infection and Immunity,vol.
79, no. 1, pp. 414–420, 2011.
[ 6 0 ] M .J .R o m a n ,P .D .C o ri z ,a n dO .G .B a c a ,“ Ap r o p o s e dm o d e l
to explain persistent infection of host cells with Coxiella
burnetii,” Journal of General Microbiology, vol. 132, no. 5, pp.
1415–1422, 1986.
[61] T. F. McCaul and J. C. Williams, “Developmental cycle of
Coxiella burnetii: structure and morphogenesis of vegetativeInternational Journal of Microbiology 15
and sporogenic diﬀerentiations,” Journal of Bacteriology, vol.
147, no. 3, pp. 1063–1076, 1981.
[62] T. F. McCaul, T. Hackstadt, and J.C. Williams, “Ultra-
structural and biological aspects of Coxiella burnetii under
physicaldisruption,”inRickettsiaeandRickettsialDiseases,W .
Burdorfer and R. L. Anacker, Eds., pp. 267–280, Academic
Press, New York, NY, USA, 1981.
[63] T. F. McCaul, J. C. Williams, and H. A. Thompson, “Electron
microscopy of Coxiella burnetii in tissue culture. Induction
of cell types as products of developmental cycle,” Acta
Virologica, vol. 35, no. 6, pp. 545–556, 1991.
[64] J. E. Samuel, “Developmental cycle of Coxiella burnetii,” in
Procaryotic Development, Y. V. Brun and L. J. Shimkets, Eds.,
pp. 427–440, ASM Press, Washington, DC, USA, 2000.
[65] B. Babudieri, “Research on the behavior of Coxiella burnetii
in relation to various physical and chemical agents,” Ren-
diconti dell’Istituto Superiore di Sanit, vol. 13, pp. 739–743,
1950.
[66] S. A. Coleman, E. R. Fischer, D. Howe, D. J. Mead, and R.
A. Heinzen, “Temporal analysis of Coxiella burnetii morpho-
logical diﬀerentiation,” Journal of Bacteriology, vol. 186, no.
21, pp. 7344–7352, 2004.
[67] T. N. Khavkin, “Pathologo-anatomic and experimental study
of the morphology of Q-fever,” Arkhiv Patologii, vol. 39, no.
2, pp. 75–84, 1977.
[68] A. A. Izzo and B. P. Marmion, “Variation in interferon-
gamma responses to Coxiella brunetii antigens with lympho-
cytes from vaccinated or naturally infected subjects,” Clinical
and Experimental Immunology, vol. 94, no. 3, pp. 507–515,
1993.
[69] K. J. Helbig, S. L. Heatley, R. J. Harris, C. G. Mullighan, P. G.
B a r d y ,a n dB .P .M a r m i o n ,“ V a r i a t i o ni ni m m u n er e s p o n s e
genes and chronic Q fever. Concepts: preliminary test with
post-Q fever fatigue syndrome,” Genes and Immunity, vol. 4,
no. 1, pp. 82–85, 2003.
[70] J. G. Shannon, D. C. Cockrell, K. Takahashi, G. L. Stahl, and
R. A. Heinzen, “Antibody-mediated immunity to the obli-
gate intracellular bacterial pathogen Coxiella burnetii is Fc
receptor-andcomplement-independent,”BMCImmunology,
vol. 10, article 26, 2009.
[71] Y. Morisawa, H. Wakiguchi, T. Takechi, T. Kurashige, and
H. Nagaoka, “Intractable Q fever treated with recombinant
gamma interferon,” Pediatric Infectious Disease Journal, vol.
20, pp. 546–547, 2001.
[72] H. C. Maltezou and D. Raoult, “Q fever in children,” The
Lancet Infectious Diseases, vol. 2, no. 11, pp. 686–691, 2002.
[73] M. Nov´ ak, R. Brezina, and J. Kaz´ ar, “Immunoblot analysis
of antibody response in mice infected with Coxiella burnetii
phase I,” Acta Virologica, vol. 36, no. 1, pp. 39–44, 1992.
[74] A. Vigil, R. Ortega, R. Nakajima-Sasaki et al., “Genome-wide
proﬁling of humoral immune response to Coxiella burnetii
infection by protein microarray,” Proteomics, vol. 10, no. 12,
pp. 2259–2269, 2010.
[ 7 5 ]L .R .H e n d r i x ,J .E .S a m u e l ,a n dL .P .M a l l a v i a ,“ D i ﬀerenti-
ation of Coxiella burnetii isolates by analysis of restriction-
endonuclease-digested DNA separated by SDS-PAGE,” Jour-
nal of General Microbiology, vol. 137, no. 2, pp. 269–276,
1991.
[76] G. Q. Zhang and J. E. Samuel, “Identiﬁcation and cloning
potentially protective antigens of Coxiella burnetii using sera
from mice experimentally infected with nine mile phase I,”
AnnalsoftheNewYorkAcademyofSciences,vol. 990, pp. 510–
520, 2003.
[77] G. Zhang, K. Kiss, R. Seshadri, L. R. Hendrix, and J. E.
Samuel, “Identiﬁcation and cloning of immunodominant
antigensofCoxiellaburnetii,” Infection and Immunity,vol.72,
no. 2, pp. 844–852, 2004.
[78] G. Zhang, H. To, K. E. Russell et al., “Identiﬁcation and
characterization of an immunodominant 28-kilodalton Cox-
iella burnetii outer membrane protein speciﬁc to isolates
associated with acute disease,” Infection and Immunity, vol.
73, no. 3, pp. 1561–1567, 2005.
[79] C. Chen, C. Dow, P. Wang et al., “Identiﬁcation of CD4+
T cell epitopes in C. burnetii antigens targeted by antibody
responses,” PLoS ONE, vol. 6, no. 3, Article ID e17712, 2011.
[ 8 0 ]F .T .K o s t e r ,J .C .W i l l i a m s ,a n dJ .S .G o o d w i n ,“ C e l l u l a r
immunity in Q fever: speciﬁc lymphocyte unresponsiveness
in Q fever endocarditis,” Journal of Infectious Diseases, vol.
152, no. 6, pp. 1283–1289, 1985.
[ 8 1 ]F .T .K o s t e r ,J .C .W i l l i a m s ,a n dJ .S .G o o d w i n ,“ C e l l u l a r
immunity in Q fever: modulation of responsiveness by a
suppressor T cell-monocyte circuit,” Journal of Immunology,
vol. 135, no. 2, pp. 1067–1072, 1985.
[82] J. G. Shannon, D. Howe, and R. A. Heinzen, “Virulent
Coxiella burnetii does not activate human dendritic cells: role
of lipopolysaccharide as a shielding molecule,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 102, no. 24, pp. 8722–8727, 2005.
[83] K. Polydorou, “Q fever in Cyprus: a short review,” British
Veterinary Journal, vol. 137, no. 5, pp. 470–477, 1981.
[84] H. H. Welsh, E. H. Lennette, F. R. Abinanti, and J. F. Winn,
“Air-borne transmission of Q fever: the role of parturition in
the generation of infective aerosols,” Annals of the New York
Academy of Sciences, vol. 70, no. 3, pp. 528–540, 1958.
[85] H. Tissot-Dupont, S. Torres, M. Nezri, and D. Raoult,
“Hyperendemic focus of Q fever related to sheep and wind,”
American Journal of Epidemiology, vol. 150, no. 1, pp. 67–74,
1999.
[86] K. E. Russell-Lodrigue, G. Q. Zhang, D. N. McMurray, and
J. E. Samuel, “Clinical and pathologic changes in a guinea
pig aerosol challenge model of acute Q fever,” Infection and
Immunity, vol. 74, no. 11, pp. 6085–6091, 2006.
[87] W. D. Tigertt, A. S. Benenson, and W. S. Gochenour,
“Airborne Q fever,” Bacteriological Reviews, vol. 25, pp. 285–
293, 1961.
[88] EFSA 2010a: Scientiﬁc opinion on Q fever, “EFSA panel on
animal and welfare and EFSA panel on biological hazards,”
EFSA Journal, vol. 8, no. 5, 1595.
[89] G. H. Lang, “Coxiellosis in animals,” in QF e v e r .V o l .1 .T h e
Disease, pp. 23–48, CRC Press, Boca Raton, Fla, USA, 1990.
[90] R. Guatteo, F. Beaudeau, D. Ledoux, E. Le Drean, and H.
Seegers, “Risk of false-negative results when delaying PCR
from sampling for Coxiella burnetii d e t e c t i o ni nd a i r yc o w s , ”
R e v u ed eM e d e c i n eV e t e r i n a i r e , vol. 158, no. 12, pp. 641–644,
2007.
[91] V.M.Vaidya,S.V.S.Malik,K.N.Bhilegaonkar,R.S.Rathore,
S. Kaur, and S. B. Barbuddhe, “Prevalence of Q fever in
domestic animals with reproductive disorders,” Comparative
Immunology, Microbiology and InfectiousDiseases, vol. 33, no.
4, pp. 307–321, 2010.
[92] R. Guatteo, F. Beaudeau, M. Berri, A. Rodolakis, A. Jolyc,
and H. Seegers, “Shedding routes of Coxiella burnetii in dairy
cows: implications for detection and control,” Veterinary
Research, vol. 37, no. 6, pp. 827–833, 2006.
[93] H. To, N. Kako, G. Q. Zhang et al., “Q fever pneumonia in
children in Japan,” Journal of Clinical Microbiology, vol. 34,
no. 3, pp. 647–651, 1996.16 International Journal of Microbiology
[94] H. To, K. K. Htwe, N. Kako et al., “Prevalence of Coxiella bur-
netii Infection in Dairy Cattle with Reproductive Disorders,”
Journal of Veterinary Medical Science, vol. 60, no. 7, pp. 859–
861, 1998.
[95] T. Hatchette, N. Campbell, H. Whitney, R. Hudson, and T. J.
Marrie,“SeroprevalenceofCoxiellaburnetiiinselectedpopu-
lations of domestic ruminants in Newfoundland,” Canadian
Veterinary Journal, vol. 43, no. 5, pp. 363–364, 2002.
[96] N. Okimoto, N. Asaoka, K. Osaki et al., “Clinical features of
Q fever pneumonia,” Respirology, vol. 9, no. 2, pp. 278–282,
2004.
[97] A. Rodolakis, M. Berri, C. H´ echard et al., “Comparison of
Coxiella burnetii shedding in milk of dairy bovine, caprine,
and ovine herds,” Journal of Dairy Science, vol. 90, no. 12, pp.
5352–5360, 2007.
[98] M. Berri, E. Rousset, J. L. Champion, P. Russo, and A.
Rodolakis, “Goats may experience reproductive failures and
shed Coxiella burnetii at two successive parturitions after a Q
fever infection,” Research in Veterinary Science, vol. 83, no. 1,
pp. 47–52, 2007.
[99] E. Rousset, M. Berri, B. Durand et al., “Coxiella burnetii
shedding routes and antibody response after outbreaks of
Q fever-induced abortion in dairy goat herds,” Applied and
Environmental Microbiology, vol. 75, no. 2, pp. 428–433,
2009.
[100] T. J. Marrie and D. Raoult, “Q fever—a review and issues
for the next century,” International Journal of Antimicrobial
Agents, vol. 8, no. 3, pp. 145–161, 1997.
[101] M. Berri, E. Rousset, J. L. Champion et al., “Ovine manure
used as a garden fertiliser as a suspected source of human Q
fever,” Veterinary Record, vol. 153, no. 9, pp. 269–270, 2003.
[102] AFSSA, “Fi` evre Q : rapport sur l’´ evaluation des risques pour
la sant´ e publique et des outils de gestion des risques en
´ elevage de ruminants,” pp. 1–88, 2004.
[103] W.W.Benson,D.W.Brock,andJ.Mather,“Serologicanalysis
of a penitentiary group using raw milk from a Q fever in-
fected herd,” Public Health Reports, vol. 78, pp. 707–710,
1963.
[104] E. R. Krumbiegel and H. J. Wisniewski, “Q fever in the
Milwaukee area. II. Consumption of infected raw milk by
humanvolunteers,”ArchivesofEnvironmentalHealth,vol.21,
no. 1, pp. 63–65, 1970.
[105] E. Dorko, Z. Kalinov´ a, and E. Pilipˇ cinec, “Seroprevalence of
Coxiella burnetii antibodies among students of the faculty of
medicine in Koˇ sice (Slovakia),” Folia Microbiologica, vol. 53,
no. 6, pp. 563–568, 2008.
[106] B. P. Marmion and M. G. Stoker, “The varying epidemiology
of Q fever in the southeast region of Great Britain. II. In two
rural areas,” The Journal of hygiene, vol. 54, no. 4, pp. 547–
561, 1956.
[107] A. Watanabe and H. Takahashi, “Diagnosis and treatment
of Q fever: attempts to clarify current problems in Japan,”
Journal of Infection and Chemotherapy, vol. 14, no. 1, pp. 1–7,
2008.
[108] D. L. Deutch and E. T. Peterson, “Q fever: transmission from
one human being to others,” Journal of the American Medical
Association, vol. 143, no. 4, pp. 348–350, 1950.
[109] D.RaoultandA.Stein,“Qfeverduringpregnancy—ariskfor
women, fetuses, and obstetricians,” The New England Journal
of Medicine, vol. 330, no. 5, p. 371, 1994.
[110] D. Kruszewska, K. Lembowicz, and S. Tylewska-Wierz-
banowska, “Possible sexual transmission of Q fever among
humans,” Clinical Infectious Diseases, vol. 22, no. 6, pp. 1087–
1088, 1996.
[111] A. Milazzo, R. Hall, P. A. Storm, R. J. Harris, W. Winslow,
and B. P. Marmion, “Sexually transmitted Q fever,” Clinical
Infectious Diseases, vol. 33, no. 3, pp. 399–402, 2001.
[112] M.H.Miceli,A.K.Veryser,A.D.Anderson,D.Hoﬁnger,S.A.
Lee, and C. Tancik, “A case of person-to-person transmission
of Q fever from an active duty serviceman to his spouse,”
Vector-Borne and Zoonotic Diseases, vol. 10, no. 5, pp. 539–
541, 2010.
[113] Anonymous, “Comment on Q fever transmitted by blood
transfusion-United States,” Canada Diseases Weekly Report,
vol. 3, article 201, 1977.
[114] C. E. Delsing and B. J. Kullberg, “Q fever in the Netherlands:
a concise overview and implications of the largest ongoing
outbreak,” Netherlands Journal of Medicine, vol. 66, no. 9, pp.
365–367, 2008.
[115] J. B. Harman, “Q fever in Great Britain; clinical account of
eight cases,” The Lancet, vol. 254, no. 6588, pp. 1028–1030,
1949.
[116] H. J. Gerth, U. Leidig, and Riemenschneider Th., “Q-fever
epidemic in an Institute of Human Pathology,” Deutsche
Medizinische Wochenschrift, vol. 107, no. 37, pp. 1391–1395,
1982.
[117] A. Stein and D. Raoult, “Q fever during pregnancy: a public
health problem in Southern France,” Clinical Infectious Dis-
eases, vol. 27, no. 3, pp. 592–596, 1998.
[118] Anonymous, “Experimental Q fever in man,” British Medical
Journal, vol. 1, article 1000, 1950.
[119] R. J. Bildfell, G. W. Thomson, D. M. Haines, B. J. McEwen,
a n dN .S m a r t ,“ Coxiella burnetii infection is associated with
placentitis in cases of bovine abortion,” Journal of Veterinary
Diagnostic Investigation, vol. 12, no. 5, pp. 419–425, 2000.
[120] M. S. Hansen, A. Rodolakis, D. Cochonneau et al., “Coxiella
burnetii associated placental lesions and infection level in
parturient cows,” Veterinary Journal. In press.
[121] M. Plommet, M. Capponi, J. Gestin, and G. Renoux,
“Experimental Q fever in cattle,” Annales de Recherches
Veterinaires, vol. 4, no. 2, pp. 325–346, 1973.
[122] F. Beaudeau, R. Guatteo, and H. Seegers, “Excretion of
Coxiella burnetii by dairy cows: consequences for disease
screening and control,” ´ Epid´ emiologie et Sant´ e Animale, vol.
49, pp. 1–4, 2006.
[123] G. Czaplicki, J.-Y. Houtain, C. Mullender, C. Manteca, and C.
Saegerman, “Le lait de tank, outil ﬁable pour le diagnostic de
la ﬁ` evre Q dans le troupeau bovin laitier?” ´ Epid´ emiologie et
Sant´ e Animale, vol. 56, pp. 117–127, 2009.
[124] A. L. Garc´ ıa-P´ erez, I. Astobiza, J. F. Barandika, R. Atxaeran-
dio, A. Hurtado, and R. A. Juste, “Short communication:
investigation of Coxiella burnetii occurrence in dairy sheep
ﬂocks by bulk-tank milk analysis and antibody level deter-
mination,” Journal of Dairy Science, vol. 92, no. 4, pp. 1581–
1584, 2009.
[125] C. Dubuc-Forfait, E. Rousset, J. L. Champion et al.,
“D´ emarche d’appr´ eciation du risque d’excr´ etion de Coxiella
burnetiidanslestroupeauxcaprinslaitirsdanslesud-estdela
France,” ´ Epid´ emiologieetSant´ eAnimale,vol.55,pp.117–136,
2009.
[126] R. Guatt´ eo, F. Beaudeau, A. Joly, and H. Seegers, “Assessing
the within-herd prevalence of Coxiella burnetii milk-shedder
cows using a real-time PCR applied to bulk tank milk,”
Zoonoses and Public Health, vol. 54, no. 5, pp. 191–194, 2007.
[127] T. J. Marrie, “Acute Q fever,” in Q Fever. The disease,T .J .
Marrie, Ed., pp. 125–160, CRC Press, Boca Raton, Fla, USA,
1990.International Journal of Microbiology 17
[128] R. Guatteo, A. Joly, A. Rodolakis et al., “Pr´ evention de
l’excr´ etion de Coxiella burnetii ` a l’aide d’un vaccin dit
phase I (Coxevac en troupeaux bovines laitiers infect´ es),”
Rencontres autour des Recherches sur les Ruminants, vol. 15,
pp. 59–62, 2008.
[129] A. F. Taurel, R. Guatteo, A. Joly, H. Seegers, and F. Beaudeau,
“Seroprevalence of Q fever in naturally infected dairy cattle
herds,” Preventive Veterinary Medicine, vol. 101, no. 1-2, pp.
51–57, 2011.
[130] B. Schimmer, G. Morroy, F. Dijkstra et al., “Large ongoing Q
fever outbreak in the south of The Netherlands, 2008,” Euro
Surveillance, vol. 13, no. 31, article 2, 2008.
[131] C. H. W. Klaassen, M. H. Nabuurs-Franssen, J. J. H. C.
Tilburg, M. A. W. M. Hamans, and A. M. Horrevorts,
“Multigenotype Q fever outbreak, the Netherlands,” Emerg-
ing Infectious Diseases, vol. 15, no. 4, pp. 613–614, 2009.
[132] V. M. Vaidya, S. V. S. Malik, S. Kaur, S. Kumar, and S.
B. Barbuddhe, “Comparison of PCR, immunoﬂuorescence
assay, and pathogen isolation for diagnosis of Q fever in
humans with spontaneous abortions,” Journal of Clinical
Microbiology, vol. 46, no. 6, pp. 2038–2044, 2008.
[133] J. S´ anchez, A. Souriau, A. J. Buend´ ıa et al., “Experimental
Coxiella burnetii infection in pregnant goats: a histopatho-
logical and immunohistochemical study,” Journal of Compar-
ative Pathology, vol. 135, no. 2-3, pp. 108–115, 2006.
[134] N. A. Bouvery, A. Souriau, P. Lechopier, and A. Rodolakis,
“Experimental Coxiella burnetii infection in pregnant goats:
excretion routes,” Veterinary Research, vol. 34, no. 4, pp. 423–
433, 2003.
[135] N. Arricau-Bouvery, A. Souriau, C. Bodier, P. Dufour, E.
Rousset, and A. Rodolakis, “Eﬀect of vaccination with phase
I and phase II Coxiella burnetii vaccines in pregnant goats,”
Vaccine, vol. 23, no. 35, pp. 4392–4402, 2005.
[136] M. Berri, E. Rousset, C. Hechard et al., “Progression of Q
feverandCoxiella burnetii sheddinginmilkafteranoutbreak
of enzootic abortion in a goat herd,” Veterinary Record, vol.
156, no. 17, pp. 548–549, 2005.
[137] T. Hatchette, N. Campbell, R. Hudson, D. Raoult, and T. J.
Marrie, “Natural history of Q fever in goats,” Vector Borne
and Zoonotic Diseases, vol. 3, no. 1, pp. 11–15, 2003.
[138] R. De Cremoux, E. Rousset, A. Touratier et al., “Coxiella
burnetii vaginal shedding and antibody responses in dairy
goat herds in a context of clinical Q fever outbreaks,” in
Proceedings of the 6th International Meeting on Rickettsiae and
Rickettsial diseases, Heraklion, Crete, Greece, June 2011.
[139] R.DeCremoux,E.Rousset,A.Touratieretal.,“Assessmentof
vaccination by a phase I Coxiella burnetii inactivated vaccine
in goat herds in clinical Q fever situation,” in Proceedings
of the 6th International Meeting on Rickettsiae and Rickettsial
diseases, Heraklion, Crete, Greece, June 2011.
[140] M. Berri, A. Souriau, M. Crosby, D. Crochet, P. Lechopier,
and A. Rodolakis, “Relationships between the shedding of
Coxiella burnetii, clinical signs and serological responses of
34 sheep,” Veterinary Record, vol. 148, no. 16, pp. 502–505,
2001.
[141] M. Berri, A. Souriau, M. Crosby, and A. Rodolakis, “Shed-
dingofCoxiella burnetii inewesintwopregnanciesfollowing
an episode of Coxiella abortion in a sheep ﬂock,” Veterinary
Microbiology, vol. 85, no. 1, pp. 55–60, 2002.
[142] S. Panaiotov, M.Ciccozzi, N. Brankova etal., “Anoutbreakof
Q fever in Bulgaria,” Annali dell’Istituto Superiore di Sanita,
vol. 45, no. 1, pp. 83–86, 2009.
[143] I. Astobiza, J. F. Barandika, F. Ruiz-Fons et al., “Coxiella bur-
netii shedding and environmental contamination at lambing
in two highly naturally-infected dairy sheep ﬂocks after
vaccination,” Research in Veterinary Science. In press.
[144] B. P. Marmion and M. G. Stoker, “The epidemiology of Q
fever in Great Britain; an analysis of the ﬁndings and some
conclusions,” British Medical Journal, vol. 2, no. 5100, pp.
809–816, 1958.
[145] A. Mantovani and P. Benazzi, “The isolation of Coxiella bur-
netii from Rhipicephalus sanguineus on naturally infected
dogs,” Journal of the AmericanVeterinaryMedical Association,
vol. 122, no. 911, pp. 117–118, 1953.
[146] T. Kosatsky, “Household outbreak of Q-fever pneumonia
related to a parturient cat,” The Lancet, vol. 2, no. 8417-8418,
pp. 1447–1449, 1984.
[147] T.J.Marrie,J.VanBuren,andJ.Fraser,“Seroepidemiology of
Q fever among domestic animals in Nova Scotia,” American
Journal of Public Health, vol. 75, no. 7, pp. 763–766, 1985.
[148] F. Buhariwalla, B. Cann, and T. J. Marrie, “A dog-related
outbreak of Q fever,” Clinical Infectious Diseases, vol. 23, no.
4, pp. 753–755, 1996.
[149] T. J. Marrie, “Q fever, 1979–1987—Nova Scotia,” Canada
Diseases Weekly Report, vol. 14, no. 17, pp. 69–70, 1988.
[150] T. J. Marrie, A. MacDonald, H. Durant, L. Yates, and L.
McCormick,“AnoutbreakofQfeverprobablyduetocontact
with a parturient cat,” Chest, vol. 93, no. 1, pp. 98–103, 1988.
[151] T. J. Marrie, H. Durant, J. C. Williams, E. Mintz, and
D. M. Waag, “Exposure to parturient cats: a risk factor
for acquisition of Q fever in maritime Canada,” Journal of
Infectious Diseases, vol. 158, no. 1, pp. 101–108, 1988.
[152] D. Higgins and T. J. Marrie, “Seroepidemiology of Q fever
among cats in New Brunswick and Prince Edward Island,”
AnnalsoftheNewYorkAcademyofSciences,vol. 590, pp. 271–
274, 1990.
[153] R. L. Pinsky, D. B. Fishbein, C. R. Greene, and K. F. Gen-
sheimer, “An outbreak of cat-associated Q fever in the United
States,” Journal of Infectious Diseases, vol. 164, no. 1, pp. 202–
204, 1991.
[154] L. Matthewman, P. Kelly, D. Hayter et al., “Exposure of cats
in southern africa to Coxiella burnetii, the agent of Q fever,”
European Journal of Epidemiology, vol. 13, no. 4, pp. 477–479,
1997.
[155] T. J. Marrie, D. Langille, V. Papukna, and L. Yates, “Truckin’
pneumonia—an outbreak of Q fever in a truck repair plant
probably due to aerosols from clothing contaminated by
contact with newborn kittens,” Epidemiology and Infection,
vol. 102, no. 1, pp. 119–127, 1989.
[156] J. H. Gillepsie and J. A. Baker, “Experimental Q fever in cats,”
American Journal of Veterinary Research, vol. 13, pp. 91–94,
1952.
[157] T. Komiya, K. Sadamasu, M. I. Kang, S. Tsuboshima, H.
Fukushi, and K. Hirai, “Seroprevalence of Coxiella burnetii
infections among cats in diﬀerent living environments,”
Journal of Veterinary Medical Science, vol. 65, no. 9, pp. 1047–
1048, 2003.
[158] P. Willeberg, R. Ruppanner, and D. E. Behymer, “Environ-
mental exposure to Coxiella burnetii: a sero-epidemiologic
survey among domestic animals,” American Journal of Epi-
demiology, vol. 111, no. 4, pp. 437–443, 1980.
[159] J. B. Enright, C. E. Franti, W. M. Longhurst, D. E. Behymer,
M. E. Wright, and V. J. Dutson, “Coxiella burneti in a
wildlife-livestock environment: antibody response of ewes
and lambs in an endemic q fever area,” American Journal of
Epidemiology, vol. 94, no. 1, pp. 62–71, 1971.
[160] H. P. Riemann, R. A. Thompson, D. E. Behymer, and
C. Wijayasinghe, “Toxoplasmosis and Q fever antibodies18 International Journal of Microbiology
among wild carnivores in California,” Journal of Wildlife
Management, vol. 42, pp. 198–202, 1978.
[161] J. P. Webster, G. Lloyd, and D. W. MacDonald, “Q fever (Cox-
iellaburnetii)reservoirin wild brown rat(Rattusnorvegicus)
populations in the UK,” Parasitology, vol. 110, no. 1, pp. 31–
35, 1995.
[162] I. Astobiza, M. Barral, F. Ruiz-Fons et al., “Molecular in-
vestigation of the occurrence of Coxiella burnetii in wildlife
and ticks in an endemic area,” Veterinary Microbiology, vol.
147, no. 1-2, pp. 190–194, 2011.
[163] F. Ruiz-Fons, ´ O. Rodr´ ıguez, A. Torina, V. Naranjo, C.
Gort´ azar, and J. de la Fuente, “Prevalence of Coxiella
burnetti infection in wild and farmed ungulates,” Veterinary
Microbiology, vol. 126, no. 1–3, pp. 282–286, 2008.
[164] H. R. Cox, “A ﬁlter-passing infectious agent isolated from
ticks. III. Description of organisms and cultivation experi-
ments,” Public Health Reports, vol. 53, pp. 2270–2276, 1938.
[165] R. R. Parker and G. E. Davis, “A ﬁlter-passing infectious
agent isolated from ticks. II. Transmission by Dermacentor
andersoni,” Public Health Reports, vol. 53, pp. 2267–2269,
1938.
[166] G. E. Davis, “Rickettsia diaporica: recovery of three strains
from Dermacentor andersoni collected in southeastern Wy-
oming: their identity with Montana strain 1,” Public Health
Reports, vol. 54, pp. 2219–2225, 1939.
[167] H. R. Cox, “Rickettsia diaporica and American Q fever,”
American Journal of Tropical Medicine and Hygiene, vol. 20,
pp. 463–465, 1940.
[168] D. J. W. Smith, “Studies on the epidemiology of Q fever.
III. The transmission of Q fever by the tick Haemaphysalis
humerosa,” Australian Journal of Experimental Biology &
Medical Science, vol. 18, pp. 103–106, 1940.
[169] D. J. W. Smith and E. H. Derrick, “Studies on the epidemiol-
ogy of Q fever. I. Isolation of six strains of Rickettsia burnetii
from the tick Haemaphysalis humerosa,” Australian Journal
of Experimental Biology & Medical Science, vol. 18, pp. 1–5,
1940.
[170] D. J. W. Smith, “Studies on the epidemiology of Q fever.
VIII. The transmission of Q fever by the tick Rhipicephalus
sanguineus,” Australian Journal of Experimental Biology &
Medical Science, vol. 19, pp. 119–122, 1941.
[171] J. H. Pope, W. Scott, and R. Dweyer, “Coxiella burnetii
in kangaroos and kangorro-ticks in Western Queenland,”
Annual Report of the Australian Medical, vol. 9, pp. 214–216,
1960.
[172] S. Pluta, K. Hartelt, R. Oehme, U. Mackenstedt, and P.
Kimmig, “Prevalence of Coxiella burnetii and Rickettsia spp.
in ticks and rodents in southern Germany,” Ticks and Tick-
Borne Diseases, vol. 1, no. 3, pp. 145–147, 2010.
[173] A. Hildebrandt, E. Straube, H. Neubauer, and G. Schmoock,
“Coxiella burnetii and coinfections in ixodes ricinus ticks in
Central Germany,” Vector-Borne and Zoonotic Diseases, vol.
11, no. 8, pp. 1205–1207, 2011.
[174] T. J. Marrie, J. C. Williams, W. F. Schlech, and L. Yates, “Q
fever pneumonia associated with exposure to wild rabbits,”
The Lancet, vol. 1, no. 8478, pp. 427–429, 1986.
[175] C. B. Philip, “Observations on experimental Q fever,” In-
ternational Journal for Parasitology, vol. 34, pp. 457–464,
1948.
[176] P. Giroud and J. Jardin, “Infection latent et conservation de
Rickettsiaburnettiichezl’homme:lerˆ oledupou,”LeBulletin
de la Soci´ et´ ed eP a t h o l o g i eE x o t i q u e , vol. 45, pp. 764–765,
1954.
[177] H.F.Gidding,C.Wallace,G.L.Lawrence,andP.B.McIntyre,
“Australia’s national Q fever vaccination program,” Vaccine,
vol. 27, no. 14, pp. 2037–2041, 2009.
[178] T. J. Marrie, A. Stein, D. Janigan, and D. Raoult, “Route of
infection determines the clinical manifestations of acute Q
fever,” Journal of Infectious Diseases, vol. 173, no. 2, pp. 484–
487, 1996.
[179] J. C. Williams, “Infectivity, virulence, and pathogenicity of
Coxiella burnetii for various hosts,” in QF ev e r :T h eB i o l o gyo f
Coxiella burnetii, J. C. Williams and H. A. Thompson, Eds.,
pp. 21–71, CRC Press, Boca Raton, Fla, USA, 1991.
[180] J.D.Hartzell,S.W.Peng,R.N.Wood-Morrisetal.,“Atypical
Q fever in United States armed soldiers,” Emerging Infectious
Diseases, vol. 13, pp. 1247–1249, 2007.
[181] N.Okimoto,T.Kibayashi,K.Mimuraetal.,“Coxiellaburnetii
and acute exacerbations/infections in patients with chronic
lung disease,” Respirology, vol. 12, no. 4, pp. 619–621, 2007.
[182] F. Fenollar, P. E. Fournier, M. P. Carrieri, G. Habib, T.
Messana, and D. Raoult, “Risks factors and prevention of Q
fever endocarditis,” Clinical Infectious Diseases, vol. 33, no. 3,
pp. 312–316, 2001.
[183] F. Fenollar, F. Thuny, B. Xeridat, H. Lepidi, and D. Raoult,
“Endocarditis after acute Q fever in patients with previously
undiagnosed valvulopathies,” Clinical Infectious Diseases, vol.
42, no. 6, pp. 818–821, 2006.
[184] B. Kaplan, D. Rabinerson, S. Ben-Ari, A. Neri, and P.
Merlob, “An isolated case of Q-fever during pregnancy,” Acta
Obstetricia et Gynecologica Scandinavica, vol. 74, no. 10, pp.
848–849, 1995.
[185] D. Raoult, F. Fenollar, and A. Stein, “Q fever during preg-
nancy: diagnosis, treatment, and follow-up,” Archives of In-
ternal Medicine, vol. 162, no. 6, pp. 701–704, 2002.
[186] X. Carcopino, D. Raoult, F. Bretelle, L. Boubli, and A. Stein,
“Managing Q fever during pregnancy: the beneﬁts of long-
term cotrimoxazole therapy,” Clinical Infectious Diseases, vol.
45, no. 5, pp. 548–555, 2007.
[187] V. A. Barss, B. R. Benacerraf, and F. D. Frigoletto Jr.,
“Second trimester oligohydramnios, a predictor of poor fetal
outcome,” Obstetrics and Gynecology, vol. 64, no. 5, pp. 608–
610, 1984.
[188] T. S. Moore, J. Longo, G. R. Leopold, G. Casola, and B.
B. Gosink, “The reliability and predictive value of an am-
niotic ﬂuid scoring system in severe second-trimester oligo-
hydramnios,” Obstetrics and Gynecology, vol. 73, no. 5, pp.
739–742, 1989.
[189] H. Tissot-Dupont, D. Raoult, P. Brouqui et al., “Epidemio-
logic features and clinical presentation of acute Q fever in
hospitalized patients: 323 French cases,” American Journal of
Medicine, vol. 93, no. 4, pp. 427–434, 1992.
[190] P. E. Fournier, J. Etienne, J. R. Harle, G. Habib, and D.
Raoult, “Myocarditis, a rare but severe manifestation of Q
fever: report of 8 cases and review of the literature,” Clinical
Infectious Diseases, vol. 32, no. 10, pp. 1440–1447, 2001.
[191] X. Carcopino, D. Raoult, F. Bretelle, L. Boubli, and A. Stein,
“Qfeverduringpregnancy:acauseofpoorfetalandmaternal
outcome,” Annals of the New York Academy of Sciences, vol.
1166, pp. 79–89, 2009.
[192] P. E. Fournier, T. J. Marrie, and D. Raoult, “Diagnosis of
Qf e v e r , ”Journal of Clinical Microbiology, vol. 36, no. 7, pp.
1823–1834, 1998.
[193] F. Fenollar, P. E. Fournier, and D. Raoult, “Molecular
detection of Coxiella burnetii in the sera of patients with Q
fever endocarditis or vascular infection,” Journal of Clinical
Microbiology, vol. 42, no. 11, pp. 4919–4924, 2004.International Journal of Microbiology 19
[194] I. Hickie, T. Davenport, D. Wakeﬁeld et al., “Post-infective
andchronicfatiguesyndromesprecipitatedbyviralandnon-
viral pathogens: prospective cohort study,” British Medical
Journal, vol. 333, no. 7568, pp. 575–578, 2006.
[195] N. R. Parker, J. H. Barralet, and A. M. Bell, “Q fever,” The
Lancet, vol. 367, no. 9511, pp. 679–688, 2006.
[196] J. Schuil, J. H. Richardus, G. S. Baarsma, and G. J. P. Schaap,
“Q fever as a possible cause of bilateral optic neuritis,” British
Journal of Ophthalmology, vol. 69, no. 8, pp. 580–583, 1985.
[197] Y. Shaked and Y. Samra, “Q fever meningoencephalitis
associated with bilateral abducens nerve paralysis, bilateral
optic neuritis and abnormal cerebrospinal ﬂuid ﬁndings,”
Infection, vol. 17, no. 6, pp. 394–395, 1989.
[198] E. Bernit, J. Pouget, F. Janbon et al., “Neurological involve-
ment in acute Q fever: a report of 29 cases and review of the
literature,” Archives of Internal Medicine, vol. 162, no. 6, pp.
693–700, 2002.
[199] J. M. Langley, T. J. Marrie, J. C. LeBlanc, A. Almudevar,
L. Resch, and D. Raoult, “Coxiella burnetii seropositivity
in parturient women is associated with adverse pregnancy
outcomes,” American Journal of Obstetrics and Gynecology,
vol. 189, no. 1, pp. 228–232, 2003.
[200] Y. Kuroiwa, R. Oyanagi, S. Fuse, T. Mori, H. Ueno, and H.
Tsutsumi, “Persistent hepatitis and repeated wheezing in an
infant,” Pediatric Infectious Disease Journal,v o l .2 6 ,n o .8 ,p p .
763–769, 2007.
[201] C. McCaughey, J. McKenna, C. McKenna et al., “Human
seroprevalence to Coxiella burnetii (Q fever) in Northern
Ireland,” Zoonoses and Public Health, vol. 55, no. 4, pp. 189–
194, 2008.
[202] G. J. M. Limonard, M. H. Nabuurs-Franssen, G. Weers-
Pothoﬀ et al., “One-year follow-up of patients of the ongoing
Dutch Q fever outbreak: clinical, serological and echocardio-
graphic ﬁndings,” Infection, vol. 38, no. 6, pp. 471–477, 2010.
[203] B. P. Marmion, O. Sukocheva, P. A. Storm et al., “Q fever:
persistence of antigenic non-viable cell residues of Coxiella
burnetii in the host—implications for post Q fever infection
fatigue syndrome and other chronic sequelae,” QJM: An
International Journal of Medicine, vol. 102, no. 10, pp. 673–
684, 2009.
[204] D. Raoult, T. J. Marrie, and J. L. Mege, “Natural history and
pathophysiology of Q fever,” The Lancet Infectious Diseases,
vol. 5, no. 4, pp. 219–226, 2005.
[205] E. A. S. Whitney, R. F. Massung, A. J. Candee et al., “Ser-
oepidemiologic and occupational risk survey for Coxiella
burnetii antibodies among US veterinarians,” Clinical Infec-
tious Diseases, vol. 48, no. 5, pp. 550–557, 2009.
[206] J. H. McQuiston and J. E. Childs, “Q fever in humans and
animals in the United States,” Vector-Borne and Zoonotic
Diseases, vol. 2, no. 3, pp. 179–191, 2002.
[207] B.Schimmer,R.terSchegget,M.Wegdametal.,“Theuseofa
geographic information system to identify a dairy goat farm
asthemostlikelysourceofanurbanQ-feveroutbreak,”BMC
Infectious Diseases, vol. 10, article 69, 2010.
[208] T. R. Davies, Y. Edwards, A. Morgan, and E. O. Caul, “Prev-
alence of Q fever in a rural practice,” Journal of Public Health
Medicine, vol. 19, no. 3, pp. 324–327, 1997.
[209] M. Montejo Baranda, J. Corral Carranceja, and C. Aguirre
Errasti,“QfeverintheBasqueCountry:1981–1984,”Reviews
of Infectious Diseases, vol. 7, no. 5, pp. 700–701, 1985.
[210] A. Tellez, C. Sainz, C. Echevarria et al., “Q fever in Spain:
acute and chronic cases, 1981–1985,” Reviews of Infectious
Diseases, vol. 10, no. 1, pp. 198–202, 1988.
[211] J. M. Sanzo, M. A. Garcia-Calabuig, A. Audicanat, and
V. Dehesa, “Q fever: prevalence of antibodies to Coxiella
burnetii in the Basque Country,” International Journal of
Epidemiology, vol. 22, no. 6, pp. 1183–1188, 1993.
[212] D. W. Spelman, “Q fever: a study of 111 consecutive cases,”
MedicalJournal ofAustralia,vol. 1,no. 13, pp.547–553, 1982.
[213] D. R. Thomas, R. L. Salmon, S. M. Kench et al., “Zoonotic
illness—determining risks and measuring eﬀects: association
between current animal exposure and a history of illness in
a well characterised rural population in the UK,” Journal of
Epidemiology and Community Health, vol. 48, no. 2, pp. 151–
155, 1994.
[214] D. R. Thomas, L. Treweek, R. L. Salmon et al., “The risk
of acquiring Q fever on farms: a seroepidemiological study,”
OccupationalandEnvironmentalMedicine,vol.52,no.10,pp.
644–647, 1995.
[215] M. Leone, A. Honstettre, H. Lepidi et al., “Eﬀect of sex on
Coxiella burnetii infection: protective role of 17β-estradiol,”
Journal of Infectious Diseases, vol. 189, no. 2, pp. 339–345,
2004.
[216] H. Tissot-Dupont, V. Vaillant, S. Rey, and D. Raoult, “Role of
sex, age, previous valve lesion, and pregnancy in the clinical
expression and outcome of Q fever after a large outbreak,”
Clinical Infectious Diseases, vol. 44, no. 2, pp. 232–237, 2007.
[217] P. Brouqui, H. T. Dupont, M. Drancourt et al., “Chronic
Q fever: ninety-two cases from France, including 27 cases
without endocarditis,” Archives of Internal Medicine, vol. 153,
no. 5, pp. 642–648, 1993.
[218] D. Raoult, H. Tissot-Dupont, C. Foucault et al., “Q fever
1985–1998: clinical and epidemiologic features of 1,383
infections,” Medicine, vol. 79, no. 2, pp. 109–123, 2000.
[219] M. Maurin, A. M. Benoliel, P. Bongrand, and D. Raoult,
“Phagolysosomal alkalinization and the bactericidal eﬀect
of antibiotics: the Coxiella burnetii paradigm,” Journal of
Infectious Diseases, vol. 166, no. 5, pp. 1097–1102, 1992.
[220] D. Raoult, P. Houpikian, H. Tissot-Dupont, J. M. Riss, J.
Arditi-Djiane, and P. Brouqui, “Treatment of Q fever endo-
carditis: comparison of 2 regimens containing doxycycline
and oﬂoxacin or hydroxychloroquine,” Archives of Internal
Medicine, vol. 159, no. 2, pp. 167–173, 1999.
[221] A. Gikas, D. P. Kofteridis, A. Manios, J. Pediaditis, and Y.
Tselentis, “Newer macrolides as empiric treatment for acute
Q fever infection,” Antimicrobial Agents and Chemotherapy,
vol. 45, no. 12, pp. 3644–3646, 2001.
[222] H. Tissot-Dupont and D. Raoult, “Clinical aspects, diagnosis
and treatment of Q fever,” in Rickettsial Diseases, D. Raoult
and P. Parola, Eds., pp. 291–301, Informa Healthcare USA,
New York, NY, USA, 2007.
[223] J. M. Rolain, M. N. Mallet, and D. Raoult, “Correlation
between serum doxycycline concentrations and serologic
evolution in patients with Coxiella burnetii endocarditis,”
Journal of Infectious Diseases, vol. 188, no. 9, pp. 1322–1325,
2003.
[224] J. M. Rolain, A. Boulos, M. N. Mallet, and D. Raoult,
“Correlation between ratio of serum doxycycline concen-
tration to MIC and rapid decline of antibody levels during
treatment of Q fever endocarditis,” Antimicrobial Agents and
Chemotherapy, vol. 49, no. 7, pp. 2673–2676, 2005.
[225] J. M. Rolain, F. Lambert, and D. Raoult, “Activity of
telithromycin against thirteen new isolates of C. burnetii
including three resistant to doxycycline,” Annals of the New
York Academy of Sciences, vol. 1063, pp. 252–256, 2005.20 International Journal of Microbiology
[226] P. C. Karakousis, M. Trucksis, and J. S. Dumler, “Chronic Q
fever in the United States,” Journal of Clinical Microbiology,
vol. 44, no. 6, pp. 2283–2287, 2006.
[227] B. L. A. Scola, H. Lepidi, and D. Raoult, “Pathologic changes
during acute Q fever: inﬂuence of the route of infection
and inoculum size in infected guinea pigs,” Infection and
Immunity, vol. 65, no. 6, pp. 2443–2447, 1997.
[228] G. H. Scott, J. C. Williams, and E. H. Stephenson, “Animal
models in Q fever: pathological responses of inbred mice to
phase I Coxiella burnetii,” Journal of General Microbiology,
vol. 133, no. 3, pp. 691–700, 1987.
[229] J.C.Gonder,R.A.Kishimoto,andM.D.Kastello,“Cynomol-
gus monkey model for experimental Q fever infection,”
Journal of Infectious Diseases, vol. 139, no. 2, pp. 191–199,
1979.
[230] D. M. Waag, W. R. Byrne, J. Estep, P. Gibbs, M. L. Pitt, and
C. M. Banﬁeld, “Evaluation of cynomolgus (Macaca fascicu-
laris) and rhesus (Macaca mulatta) monkeys as experimental
models of acute Q fever after aerosol exposure to phase-I
Coxiella burnetii,” Laboratory Animal Science, vol. 49, no. 6,
pp. 634–638, 1999.
[231] M. Enserink, “Questions abound in Q-fever explosion in the
Netherlands,” Science, vol. 327, no. 5963, pp. 266–267, 2010.
[232] H. I. J. Roest, J. J. H. C. Tilburg, W. van der Hoek et al., “The
Q fever epidemic in the Netherlands: history, onset, response
and reﬂection,” Epidemiology and Infection, vol. 139, no. 1,
pp. 1–12, 2011.
[233] I. Karagiannis, B. Schimmer, A. Van Lier et al., “Investigation
of a Q fever outbreak in a rural area of The Netherlands,”
Epidemiology and Infection, vol. 137, no. 9, pp. 1283–1294,
2009.
[234] H. I. J. Roest, R. C. Ruuls, J. J. H. C. Tilburg et al., “Molecular
epidemiology of Coxiella burnetii from ruminants in Q fever
outbreak, The Netherlands,” Emerging Infectious Diseases,
vol. 17, no. 4, pp. 668–675, 2011.
[235] C. J. J. Huijsmans, J. J. A. Schellekens, P. C. Wever et
al.,“Single-nucleotide-polymorphismgenotypingofCoxiella
burnetii during a Q fever outbreak in the Netherlands,”
Applied and Environmental Microbiology,v o l .7 7 ,n o .6 ,p p .
2051–2057, 2011.
[236] L. Hogerwerf, R. van den Brom, H. I.J. Roest et al.,
“Reduction of Coxiella burnetii prevalence by vaccination
of goats and sheep, The Netherlands,” Emerging Infectious
Diseases, vol. 17, no. 3, pp. 379–386, 2011.
[237] D. F. Gimenez, “Staining rickettsiae in yolk-sac cultures,”
Stain Technology, vol. 39, pp. 135–140, 1964.
[238] D. Raoult, J. C. Laurent, and M. Mutillod, “Monoclonal
antibodies to Coxiella burnetii for antigenic detection in cell
culturesandinparaﬃn-embeddedtissues,”AmericanJournal
of Clinical Pathology, vol. 101, no. 3, pp. 318–320, 1994.
[239] P. M. Dilbeck and T. F. McElwain, “Immunohistochemical
detection of Coxiella burnetti in formalin-ﬁxed placenta,”
JournalofVeterinaryDiagnosticInvestigation,v ol.6,no .1,pp .
125–127, 1994.
[240] A. Omsland, D. C. Cockrell, D. Howe et al., “Host cell-
free growth of the Q fever bacterium Coxiella burnetii,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 106, no. 11, pp. 4430–4434, 2009.
[241] D. Frangoulidis, A. Rodolakis, V. Heiser, O. Landt, W. Splett-
stoesser,andH.Meyer,“DNAmicroarray-chipbaseddiagno-
sis of Q-fever (Coxiella burnetii),” Clinical Microbiology and
Infection, vol. 15, no. 2, pp. 165–166, 2009.
[242] P. E. Fournier and D. Raoult, “Comparison of PCR and
serology assays for early diagnosis of acute Q fever,” Journal
of Clinical Microbiology, vol. 41, no. 11, pp. 5094–5098, 2003.
[243] E. Ughetto, F. Gouriet, D. Raoult, and J. M. Rolain, “Three
years experience of real-time PCR for the diagnosis of Q
fever,” Clinical Microbiology and Infection, vol. 15, supple-
ment 2, pp. 200–201, 2009.
[244] A. Stein and D. Raoult, “Detection of Coxiella burnetii by
DNAampliﬁcationusingpolymerasechainreaction,”Journal
of Clinical Microbiology, vol. 30, no. 9, pp. 2462–2466, 1992.
[245] H. Willems, D. Thiele, R. Fr¨ o l i c h - R i t t e r ,a n dH .K r a u s s ,
“Detection of Coxiella burnetii in cow’s milk using the
polymerase chain reaction (PCR),” Zentralblatt fur Veterin-
armedizin. Reihe B, vol. 41, no. 9, pp. 580–587, 1994.
[246] P. M. Schneeberger, M. H. A. Hermans, E. J. Van Hannen, J.
J. A. Schellekens, A. C. A. P. Leenders, and P. C. Wever, “Real-
time PCR with serum samples is indispensable for early
diagnosis of acute Q fever,” Clinical and Vaccine Immunology,
vol. 17, no. 2, pp. 286–290, 2010.
[247] M. Y. Hou, M. N. Hung, P. S. Lin et al., “Use of a single-tube
nested real-time PCR assay to facilitate the early diagnosis of
acute Q fever,” Japanese Journal of Infectious Diseases, vol. 64,
no. 2, pp. 161–162, 2011.
[248] M. Kramer, N. Obermajer, B. B. Matijasic, I. Rogelj, and V.
Kmetec, “Quantiﬁcation of live and dead probiotic bacteria
in lyophilized products by real-time PCR and by ﬂow
cytometry,” Applied Microbiology and Biotechnology, vol. 84,
pp. 1137–1147, 2009.
[249] N. Tatsumi, A. Baumgartner, Y. Qiao, I. Yamamoto, and K.
Yamaguchi, “Detection ofCoxiella burnetii inmarketchicken
eggs and mayonnaise,” Annals of the New York Academy of
Sciences, vol. 1078, pp. 502–505, 2006.
[250] N. Arricau-Bouvery and A. Rodolakis, “Is Q fever an emerg-
ing or re-emerging zoonosis?” Veterinary Research, vol. 36,
no. 3, pp. 327–349, 2005.
[251] S.A.V.Nguyen,H.Otsuka,G.Q.Zhangetal.,“Rapidmethod
for detection of Coxiella burnetii antibodies using high- den-
sity particle agglutination,” Journal of Clinical Microbiology,
vol. 34, no. 12, pp. 2947–2951, 1996.
[252] P. R. Field, A. Santiago, S. W. Chan et al., “Evaluation of
a novel commercial enzyme-linked immunosorbent assay
detecting Coxiella burnetii-speciﬁc immunoglobulin G for
Q fever prevaccination screening and diagnosis,” Journal of
Clinical Microbiology, vol. 40, no. 9, pp. 3526–3529, 2002.
[253] I.J.Uhaa,D.B.Fishbein,J.G.Olson,C.C.Rives,D.M.Waag,
and J. C. Williams, “Evaluation of speciﬁcity of indirect
enzyme-linkedimmunosorbentassayfordiagnosisofhuman
Qf e v e r , ”Journal of Clinical Microbiology, vol. 32, no. 6, pp.
1560–1565, 1994.
[254] O. Peter, G. Dupuis, M. G. Peacock, and W. Burgdorfer,
“Comparaison of enzyme-linked immunosorbent assay and
complement ﬁxation and indirect ﬂuorescent-antibody tests
fordetectionofCoxiellaburnetiiantibody,”JournalofClinical
Microbiology, vol. 26, pp. 1978–1982, 1987.
[255] S. Herr, H. F. Huchzermeyer, L. A. Te Brugge, C. C.
Williamson, J. A. Roos, and G. J. Schiele, “The use of a single
complement ﬁxation test technique in bovine brucellosis,
Johne’s disease, dourine, equine piroplasmosis and Q fever
serology,” The Onderstepoort Journal of Veterinary Research,
vol. 52, no. 4, pp. 279–282, 1985.
[256] O. Peter, G. Dupuis, W. Burgdorfer, and M. Peacock, “Evalu-
ation of the complement ﬁxation and indirect immunoﬂu-
orescence tests in the early diagnosis of primary Q fever,”International Journal of Microbiology 21
European Journal of Clinical Microbiology,v o l .4 ,n o .4 ,p p .
394–396, 1985.
[257] E. Rousset, B. Durand, M. Berri et al., “Comparative di-
agnostic potential of three serological tests for abortive Q
fever in goat herds,” Veterinary Microbiology, vol. 124, no. 3-
4, pp. 286–297, 2007.
[258] ACERSA, “Diagnostic d’un ´ elevage cliniquement atteint de
ﬁ` evre Q,” pp. 1–11, 2006.
[259] D. Musso and D. Raoult, “Serological cross-reactions be-
tween Coxiella burnetii and Legionella micdadei,” Clinical
andDiagnosticLaboratoryImmunology,vol.4,no.2,pp.208–
212, 1997.
[260] B. La Scola and D. Raoult, “Serological cross-reactions be-
tween Bartonella quintana, Bartonella henselae, and Coxiella
burnetii,” Journal of Clinical Microbiology,v o l .3 4 ,n o .9 ,p p .
2270–2274, 1996.
[261] H. T. Dupont, X. Thirion, and D. Raoult, “Q fever serology:
cutoﬀ determination for microimmunoﬂuorescence,” Clini-
cal and Diagnostic Laboratory Immunology, vol. 1, no. 2, pp.
189–196, 1994.
[262] M. Vardi, N. Petersil, A. Keysary, S. Rzotkiewicz, A. Laor,
and H. Bitterman, “Immunological arousal during acute Q
fever infection,” European Journal of Clinical Microbiology
and Infectious Diseases. In press.
[263] P. Brouqui, J. S. Dumler, and D. Raoult, “Immunohistologic
demonstration of Coxiella burnetii in the valves of patients
withQfeverendocarditis,”AmericanJournalofMedicine,vol.
97, no. 5, pp. 451–458, 1994.
[264] N. Arricau-Bouvery, A. Souriau, A. Moutoussamy, K. Lad-
enise, and A. Rodolakis, “Study of Coxiella burnetii excretion
in an experimental goat model and decontamination of dung
with calcium Cyanamid,” Rencontres autour des Recherches
sur les Ruminants, vol. 8, pp. 153–156, 2001.
[265] O. Cerf and R. Condron, “Coxiella burnetii and milk pas-
teurization: an early application of the precautionary princi-
ple?”EpidemiologyandInfection,vol.134,no.5,pp.946–951,
2006.
[266] G. H. Scott and J. C. Williams, “Susceptibility of Coxiella
burnetii to chemical disinfectants,” Annals of the New York
Academy of Sciences, vol. 590, pp. 291–296, 1990.
[267] C. E. Moodie, H. A. Thompson, M. I. Meltzer, and D. L.
Swerdlow, “Prophylaxis after exposure to Coxiella burnetii,”
Emerging Infectious Diseases, vol. 14, no. 10, pp. 1558–1566,
2008.
[268] United States Army Medical Research Institute for Infec-
tious Diseases, Medical Management of Biological Casualities
Handbook, The Frederick Institute, Frederick, Md, USA, 5th
edition, 2004.
[269] H. Woernle, C. Limouzin, K. Muler, and M. P. Durand, “La
ﬁ` evre Q bovine. Eﬀet de la vaccination et de l’antibioth´ erapie
sur l’´ evolution clinique et l’excr´ etion de Coxiella burnetii
dans le lait,” Bulletin de l’Academie Veterinaire de France, vol.
58, pp. 91–100, 1985.
[270] I. Astobiza, J. F. Barandika, A. Hurtado, R. A. Juste, and A.
L. Garc´ ıa-P´ erez, “Kinetics of Coxiella burnetii excretion in
a commercial dairy sheep ﬂock after treatment with oxyte-
tracycline,” Veterinary Journal, vol. 184, no. 2, pp. 172–175,
2010.
[271] E. Rousset, B. Durand, J. L. Champion et al., “Eﬃciency
of a phase 1 vaccine for the reduction of vaginal Coxiella
burnetii shedding in a clinically aﬀected goat herd,” Clinical
Microbiology and Infection, vol. 15, supplement 2, pp. 188–
189, 2009.
[272] R. Guatteo, H. Seegers, A. Joly, and F. Beaudeau, “Prevention
of Coxiella burnetii shedding in infected dairy herds using a
phase I C. burnetii inactivated vaccine,” Vaccine, vol. 26, no.
34, pp. 4320–4328, 2008.
[273] CEVA, “Vaccines,” 2010, http://www.ceva.com/en/Products/
Cattle/Vaccines.
[274] M. H. A. Hermans, C. R. J. J. Huijsmans, J. J. A. Schellekens,
P. H. M. Savelkoul, and P. C. Wever, “Coxiella burentii DNA
in goat milk after vaccination with Coxevac,” Vaccine, vol.
29, pp. 2653–2656, 2011.
[275] D. M. Waag, “Coxiella burnetii: host and bacterial responses
to infection,” Vaccine, vol. 25, no. 42, pp. 7288–7295, 2007.
[276] B. P. Marmion, “Development of Q-fever vaccines, 1937 to
1967,” Medical Journal of Australia, vol. 2, no. 24, pp. 1074–
1078, 1967.
[277] L. F. Fries, D. M. Waag, and J. C. Williams, “Safety and im-
munogenicity in human volunteers of a chloroform-meth-
anolresiduevaccineforQfever,”InfectionandImmunity,vol.
61, no. 4, pp. 1251–1258, 1993.
[278] J. Kazar, R. Brezina, and A. Palanova, “Immunogenicity
and reactogenicity of a Q fever chemovaccine in persons
professionallyexposedtoQfeverinCzechoslovakia,”Bulletin
of the World Health Organization, vol. 60, no. 3, pp. 389–394,
1982.
[279] D. L. Brooks, R. W. Ermel, C. E. Franti et al., “Q fever
vaccination of sheep: challenge of immunity in ewes,”
American Journal of Veterinary Research,v o l .4 7 ,n o .6 ,p p .
1235–1238, 1986.
[280] J. Kaz´ a r ,S .S c h r a m e k ,V .L i s´ ak, and R. Brezina, “Antigenicity
of chloroform-methanol-treated Coxiella burnetii prepara-
tions,” Acta Virologica, vol. 31, no. 2, pp. 158–167, 1987.
[281] N. Schmeer, P. Muller, J. Langel, H. Krauss, J. W. Frost, and
J. Wieda, “Q fever vaccines for animals,” Zentralblatt fur
Bakteriologie, Mikrobiologie und Hygiene, vol. 267, pp. 79–88,
1987.
[282] J. C. Williams and J. L. Cantrell, “Biological and immunolog-
ical properties of Coxiella burnetii vaccines in C57BL/10ScN
endotoxin-nonresponder mice,” Infection and Immunity, vol.
35, no. 3, pp. 1091–1102, 1982.
[283] J. R. Ackland, D. A. Worswick, and B. P. Marmion, “Vaccine
prophylaxis of Q fever—a follow-up study of the eﬃcacy of
Q-Vax (CSL) 1985–1990,” Medical Journal of Australia, vol.
160, no. 11, pp. 704–708, 1994.
[284] J. F. Bell, D. B. Lackman, A. Meis, and W. J. Hadlow,
“Recurrent reaction of site of Q fever vaccination in a
sensitized person,” Military Medicine, vol. 129, pp. 591–595,
1964.
[285] M. S. Ascher, M. A. Berman, and R. Ruppanner, “Initial
clinical and immunologic evaluation of a new phase I Q
fever vaccine and skin test in humans,” Journal of Infectious
Diseases, vol. 148, no. 2, pp. 214–222, 1983.
[286] B. P. Marmion, R. A. Ormsbee, M. Kyrkou et al., “Vaccine
prophylaxis of abattoir-associated Q fever: eight years’ expe-
rience in Australian abattoirs,” Epidemiology and Infection,
vol. 104, no. 2, pp. 275–287, 1990.
[287] G. Gefenaite, J. M. Munster, R. van Houdt, and E. Hak,
“Eﬀectiveness of the Q fever vaccine: a meta-analysis,”
Vaccine, vol. 29, no. 3, pp. 395–398, 2011.
[288] Y. X. Zhang, N. Zhi, S. R. Yu, Q. J. Li, G. Q. Yu, and X. Zhang,
“Protective immunity induced by 67 K outer membrane
p r o t e i no fp h a s eICoxiella burnetii in mice and guinea pigs,”
Acta Virologica, vol. 38, no. 6, pp. 327–332, 1994.
[289] Q. Li, D. Niu, B. Wen, M. Chen, L. Qiu, and J. Zhang, “Pro-
tectiveimmunityagainstQfeverinducedwitharecombinant22 International Journal of Microbiology
P1 antigen fused with HspB of Coxiella burnetii,” Annals of
the New York Academy of Sciences, vol. 1063, pp. 130–142,
2005.
[290] J. Tyczka, S. Eberling, and G. Baljer, “Immunization exper-
iments with recombinant Coxiella burnetii proteins in a
murine infection model,” Annals of the New York Academy of
Sciences, vol. 1063, pp. 143–148, 2005.